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1 History of version changes and amendments 
NB Versions 1 to 5 of the protocol were for the pilot study conducted before this trial. This was an 
external pilot. Version 5.1 is the original protocol used at the beginning of the main trial as reported 
here. Version 8 was the final protocol. 
Version 
No. 
Version 
Date 
Pages Description of change 
 
See summary of changes to protocol and registry, page 55  
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4 Introduction 
4.1 Summaries 
4.1.1 Lay Summary 
An increasing proportion of the population have long term health conditions. The current approach 
to managing patients with long term conditions is based on guidelines and treatment for each 
specific condition. Patients are regularly called to clinics in general practice (eg. diabetes clinics) to 
see a nurse who follows guidelines on managing that particular disease. However, there is an 
increasing awareness that many patients have multiple long term health conditions. This is known as 
multimorbidity. Patients with multimorbidity often have to attend several clinics which can be 
repetitive, inconvenient and inefficient. They see different nurses and doctors who may give 
conflicting advice. These patients may have to take a large number of drugs which can be confusing, 
difficult to remember and some combinations could be potentially dangerous. These patients 
frequently get depressed and they also sometimes complain that no-one treats them as a ‘whole 
person’ or takes their views into account. 
To address this problem, this study aims to develop and test a new approach to how GP practices 
manage patients with multimorbidity. Instead of focussing on each disease in isolation, the aim is to 
treat the whole patient in a consistent, joined-up manner in order to improve their overall quality of 
life. GP practices testing this new management system (intervention group) will be compared with 
GP practices following the current treatment system (usual care or control group). 
Specifically, patients in general practices allocated to the intervention group will be identified and 
flagged on their GP computer systems. A named nurse and doctor will be allocated to them to 
manage their care. These patients will be given a card to identify them to reception staff who will 
offer longer appointment times. Patients will also be invited for a comprehensive ‘3D’ health review 
every 6 months designed to cover all of their health issues. The patient will first see their named 
nurse who will identify the patients’ concerns and priorities (Dimensions of health), as well as 
perform any routine checks required by each of the patients’ conditions. The patients’ Drugs will be 
reviewed to check they are being correctly prescribed (without dangerous interactions), taken 
properly and where possible, to try to simplify the patients prescriptions e.g. by arranging for all of 
them to be taken once a day. The named GP will check for and treat symptoms of Depression. The 
practice will also have a linked ‘general physician’ at the local hospital whom they can contact easily 
for advice about patients with complex problems.  
Patients in general practices allocated to the usual care group will continue having their care 
managed by their GPs and practice nurses using current management practices of multiple 
appointments and clinics for each separate condition. 
We will first try out the new approach in three practices and use this experience to improve it. Then 
we aim to recruit 32 GP practices from in and around Bristol, Manchester and Glasgow to take part 
in the main study. These practices will be randomly assigned to the intervention or usual care group. 
A target of 1383 multimorbid patients from these practices will be followed up over a period of 12 
months. 
Before the practice randomisation and at 6 and 12 months into the study, participants from both 
groups will be asked to fill in questionnaires about their wellbeing, illnesses and treatments, their 
experience of their care, and what health resources they use. The research team will review the 
11 
 
notes of patients in both groups to record the number, type, duration and quality of consultations 
within general practice as well as their use of other health and social services. 
We will compare the cost of the old and new approaches (both the cost to the NHS and the cost to 
the patient) and relate this to the benefit in a cost-effectiveness analysis. 
We will check whether the care provided in the intervention practices actually changed the way 
intended. Through interviews with patients and care staff, and by direct observation, we will explore 
how well the approach was implemented and how it could be improved. 
 
4.1.2 Scientific Summary of research 
AIM: The aim is to optimise, implement and evaluate an intervention to improve the management of 
patients with multimorbidity in general practice 
Design: Pragmatic cluster randomised controlled trial with nested process evaluation and economic 
analysis of cost effectiveness. 
Setting: 3 practices (2 in Bristol and 1 in Manchester) will participate in a pilot phase followed by 
approximately 32 GP practices in Bristol, Glasgow and Manchester. Only practices with a minimum 
of 3 GP partners and minimum practice list size of 4,500 patients will be approached in order to 
ensure an adequate number of participants per practice. 
Participants: 
A target of 1383 participants from 32 GPs will be recruited to the study. Eligible participants will be 
18 or over with multimorbidity, defined as having three or more long term conditions (LTC) from a 
predefined list of conditions. 
Interventions 
GP practices will be randomised to the intervention or usual care groups.  
A. Intervention group: 
This is also described as the ‘new approach’ group. The intervention is designed to address the 
problems of illness burden (poor quality of life, depression) treatment burden (multiple unco-
ordinated appointments, polypharmacy, poor primary/secondary care co-ordination) and lack of 
patient-centred care (low continuity, disregard of patients’ priorities) experienced by patients with 
multimorbidity. 
There are 4 main components of the intervention 
1. Identification and prioritisation of patients with multimorbidity – given ‘3D’ card + 
flagged records. 
2. Improving continuity of care – defined usual GP and usual practice nurse. Offered longer 
appointment times. 
3. Reducing the burden of illness and treatment – comprehensive assessment every 6 
months. Each 3D assessment consists of 2 appointments approximately 1 week apart. At 
the first appointment, the patients’ usual nurse will complete a bespoke computerised 
template to address all of the 3D elements, collect relevant data in relation to the 
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patient’s combination of LTCs, and organise necessary tests. At the second appointment, 
the usual GP will review all the information, conduct a thorough review of medication 
and agree an written care plan with the patient for them to take away. The ‘3D’ label 
provides a mnemonic for health professionals. It refers to: 
 Dimensions of Health – patient’s concerns and priorities, addressing quality of 
life issues first 
 Depression – Assessment and treatment 
 Drugs – Doctors will seek to simplify treatment regimes and improve medication 
adherence, aided by prior pharmacist review of patient’s medication regime 
4. Improving integration – each practice has a designated general physician who is readily 
available to discuss multimorbidity patients with complex needs and help co-ordinate 
hospital investigations. 
 
To ensure the intervention is effectively implemented, it will be incentivised as if it were an 
Enhanced Service or included in the Quality and Outcomes Framework (QOF), with payment against 
targets for completion of two 3D assessments per annum. Practices will train in local collaboratives 
to share ideas. We will allow local adaptation, appoint a practice champion, provide training and 
monthly feedback on performance e.g. number of patients with care plans. 
B. Control group: 
Practices in the care as usual group, will continue their usual practice following disease specific 
computerised protocols focussing on data related to QOF targets. 
Outcomes 
Outcomes will be collected at baseline, 6 months and 12 month post-randomisation. 
The primary outcome will be Health Related Quality of Life as measured by the EQ-5D-5L at 12 
months post randomisation. 
Secondary outcome measures will include: 
Burden of illness measures: 
 Self-rated health 
 Bayliss measure of illness burden in multimorbidity 
 Quality of disease management (composite measure of QOF achievement) 
 Hospital Anxiety Depression Scale (HADS) 
Burden of Treatment measures: 
 Brief Treatment Burden Questionnaire 
 Morisky Medication Adherence Scale (MMAS, 8 item) 
 Number of drugs prescribed 
 Reduction in high risk drug combinations 
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Experience of patient centred care: 
 CARE measure and how well you know your doctor 
 Coordination of care and care related to patients priorities (questions from LTC6 QIPP) 
 Management of LTCs (PACIC) 
 Overall satisfaction (single item) 
Use of resources: 
 Hospital admission and outpatient rates 
 Use of health services in primary, community and secondary care 
 Investigations 
 Prescribed medication 
Socio-demographic measures (measured at baseline only): 
 Number of long term conditions 
 Age 
 Gender 
 Education 
 Ethnicity 
 Deprivation status 
 Work status 
Measures of strain on patient’s carers: 
 Carer Experience Scale 
 EQ-5D-5L completed by carers. 
 Brief Treatment Burden Questionnaire for carers 
 
Alongside the trial, a parallel mixed methods process evaluation combining quantitative and 
qualitative methods will be conducted in order to provide understanding of trial delivery, 
intervention implementation, current management practices and the responses of targeted 
participants.  
An economic evaluation will be undertaken from the perspectives of (a) NHS and personal social 
services (PSS) and (b) patients. In a cost-consequences analysis we will relate the cost of the 
intervention or usual care to changes in a range of outcomes. In a cost-effectiveness analysis from 
the NHS and PSS perspective we will estimate the incremental cost per QALY gain. Uncertainty will 
be addressed in sensitivity analyses and by using bootstrapping to estimate the net monetary 
benefit and a cost-effectiveness acceptability curve. 
Sample size: based on 32 general practices, 108 eligible patients per practice, 40% providing 
consent, we aim to recruit 1383 patients (1555 including pilot practices). With 80% follow-up at 12 
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months, and ICC at practice level of 0.03, the study will have 90% power to detect a difference 
between trial arms of 0.274 SDs in the EQ-5D.  
Benefits and potential impacts: There is widespread interest in how to improve care for patients 
with multimorbidity. If successful, this intervention could improve the quality of life of patients and 
their experience of care and reduce NHS and patient costs. By working with RCGP, we will ensure 
that if the intervention is effective, it can be implemented widely, quickly and effectively. 
4.2 Background 
In an attempt to improve the quality of care of individual long term conditions in general practice, 
care has become increasingly driven by protocols delivered using computerised templates by 
practice nurses. These nurses often have extra training in specific diseases and provide care within 
disease-specific clinics (e.g. diabetic clinics) which focus on one disease at a time. Primary care 
clinicians are incentivised through the QOF to achieve against targets relating to a limited range of 
specific long term conditions. Disease pathways for specific long term conditions are being 
developed to improve vertical integration across primary and secondary care.  
These developments fail to take account of the fact that many people have multiple long term 
conditions (multimorbidity) [1,2]. Sometimes these co-morbid conditions have a bigger impact on 
the patient’s quality of life than the specific condition being addressed at a nurse led chronic disease 
management clinic. The priorities and incentives for the health professionals dealing with a specific 
disease may or may not align with the priorities of the patient [3].  
As the population ages this problem is becoming increasingly important, since multimorbidity is 
much more common in older people [1,2]. Multimorbidity matters because people who have 
multiple conditions have poor quality of life [4], increased morbidity [5], reduced life-expectancy [6], 
and increased rates of depression [7]. Patients with multimorbidity are also a priority for the health 
service because they account for a high proportion of resource use in both primary and secondary 
care (including having high rates of hospital admissions) [8-10].  
Failing to improve care for multimorbidity will also lead to increased inequalities in health. 
Multimorbidity is more common in deprived areas [2], and patients with fewer material and 
personal resources are particularly disadvantaged by having to attend multiple appointments for 
each of their long term conditions, and being expected to follow a series of different care plans 
[11,12]. Their care is also more likely to be complicated by other medical and social factors, such as 
poor mental health, poor housing, and smoking [13]. 
The consequences of a single disease approach for the health service potentially include duplication 
and also gaps in services (e.g. conditions included in the QOF are prioritised but others are 
neglected) [14], inefficiency (because the same topics are addressed repeatedly by different 
specialist practice nurses), and waste (because of non-adherence to medication and non-attended 
appointments) [15]. If taken to its logical conclusion, the disease pathways approach would mean 
that one patient with multimorbidity would have their care managed by several specialist services 
(each crossing primary and secondary care), but there would be little co-ordination between these 
specialist services and no one professional who has an overview and takes responsibility for the 
patient as a whole. 
For patients with multimorbidity, the single disease approach is inconvenient and inefficient, 
because they are repeatedly invited to different disease-focused appointments in general practice, 
where they are asked the same questions and given the same advice (or sometimes conflicting 
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advice which can be confusing) [3,12,16,17]. Patients may receive less good quality care if the 
specialist nurse is not aware of the impact of the treatment of one disease on other diseases, which 
can be a particular problem with drug interactions. Alternatively, the disease-focused nurse or 
doctor may slavishly follow guidelines without recognising that the evidence underlying those 
guidelines is not necessarily applicable to the individual patient in front of them with multimorbidity 
(since most guidelines are based on research which excluded patients with comorbidities) [18,19]. 
If all the recommendations for each long term condition are considered in isolation and followed, 
patients with multimorbidity are likely to have numerous investigations and to be prescribed large 
numbers of drugs [20,21]. This polypharmacy can be burdensome for patients, increases the 
likelihood of interactions and adverse effects (including those causing hospital admissions), and may 
reduce medication adherence [19,22-24]. 
It is also well recognised that multimorbidity is associated with an increased prevalence of 
depression [7]. This association is strongest in deprived areas [2]. The relationship between physical 
and mental health works in both directions – people with chronic illnesses are more likely to be 
depressed, and those who are depressed are less likely to manage their long term conditions well, 
leading to worse disease control and poorer health outcomes [25]. People with multimorbidity and 
depression are also more likely to have unplanned hospital admissions [9]. The prevalence of 
comorbid depression and physical health problems is much higher in deprived areas than affluent 
areas [2]. Therefore improving mental health in people with multimorbidity is also a priority. 
Most importantly, patients with multimorbidity can feel that no one treats them as a ‘whole person’ 
rather than ‘a disease’ [3]. Patients say that they want to have a relationship with one health 
professional that they can trust, and who listens to them, helping them make appropriate decisions 
in the context of their life circumstances and values [3]. Given the large number of health problems 
they face and the number of potentially relevant investigations and treatments, they may want to 
set priorities and make trade-offs so that medication regimes are not excessively burdensome and 
they are not over-investigated. For patients, improving quality of life (which might include not 
spending too much time in contact with the health service or suffering side-effects of medication) 
might be a higher priority than achieving improved indicators of disease control with a view to 
greater longevity. 
In summary, patients with multimorbidity experience problems of illness burden (poor quality of life, 
depression) treatment burden (multiple unco-ordinated appointments, polypharmacy) and lack of 
person-centred care (low continuity, little attention paid to patients’ priorities). This research is 
designed to test the hypothesis that an intervention in general practice designed to address the 
needs and priorities of patients with multimorbidity will improve their health related quality of life 
(primary outcome), reduce their burden of illness and treatment and improve their experience of 
care, while being more cost-effective than conventional service models. This will be tested using a 
cluster RCT, with economic evaluation and mixed methods process evaluation.  
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4.3 Rationale 
There is a growing body of literature and commentary on the scale and consequences of 
multimorbidity [1,2,5,13,15,19,21,26]. Commissioners, professional bodies, academics and other 
stakeholders have all recognised the growing tension between the single disease focus of medicine 
and the needs of patients with multiple long term conditions [27]. This is evidenced by recent 
reports from the Royal College of General Practitioners [28], the Royal College of Physicians [29], 
NICE [30], and others [31]. There is a long term challenge to redesign the NHS to reflect the needs of 
patients with multiple long term conditions[32] in light of the ageing population. 
A recent Cochrane review however, highlighted the paucity of research on interventions to improve 
the outcomes of patients with multimorbidity in primary care[33]. Ten studies were identified 
examining a range of complex interventions which demonstrated mixed effects. The interventions 
that proved most effective were organisational interventions focussed on areas of concern for 
patients or where they have difficulties, such as functional ability and medication management. No 
studies included an economic analysis of cost effectiveness although a trend towards improved 
prescribing and medication adherence suggests the potential for cost savings. The conclusions of the 
systematic review called for further pragmatic studies based in primary care settings, using clear 
definitions of participants and appropriate outcomes. 
There has been considerable research on the scale of the problem and the needs of patients with 
multimorbidity [3,11,26,34-37]. Qualitative studies of patients with multimorbidity have identified 
several barriers to their self management (including depression, poor patient-clinician 
communication, poor physical function and greater financial constraints [11])as well as identifying 
what services these patients desire (including greater access, individualised care plans, continued 
care by a single coordinator of care who will listen and respond to their shifting priorities [3]).  
There are isolated examples of individual general practices trying out some of the ideas described 
above, e.g. co-ordinated assessments, although these typically focus on rationalising appointments 
rather than the extended assessment and holistic approach proposed here[38]. There is a pressing 
need for rigorous research to test the benefits and costs of a new approach to managing 
multimorbidity. 
The issues identified by the qualitative studies were confirmed by patient and carer forum meetings 
held prior to the development of the current study proposal and which informed the design of the 
intervention for the current study. The resulting complex healthcare intervention requires a large 
scale randomised controlled trial to evaluate the clinical effectiveness, cost effectiveness and 
implementation of this service. 
4.4 Study Aims and Objectives 
AIM: The aim is to optimise, implement and evaluate an intervention to improve the management of 
patients with multimorbidity in general practice 
HYPOTHESIS: An intervention in general practice designed to improve the management of 
multimorbidity will improve patients’ health related quality of life, reduce burden of illness and 
treatment and improve their experience of care whilst being more cost-effective than conventional 
service models. 
OBJECTIVES: 
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 To optimise an intervention to improve the management of multimorbidity in general 
practice through piloting in three practices. 
 To implement this intervention in a representative range of general practices 
 Through a cluster randomised controlled trial and economic evaluation, to assess the 
impact on health related quality of life, illness burden, treatment burden, patient 
experience, carer’s burden and quality of life, and cost-effectiveness. 
 Through mixed methods process evaluation, to explore how and to what extent the 
intervention was implemented, the advantages and disadvantages of different models of 
care for patients with multimorbidity, and how and why the intervention was or was not 
beneficial. We will also characterise usual care and explore any changes to management 
practices over the duration of this study in usual care GP practices. 
 To design educational materials and commissioning guides to ensure that the 
intervention is delivered consistently in practices in the trial and that if beneficial, it can be 
speedily rolled out nationally. 
 
5 Trial Design 
5.1 Study Design 
5.1.1 Study outline 
This is a multi-centre pragmatic, two-arm, practice-level cluster randomised controlled trial, with 
parallel mixed methods process evaluation and economic analysis of cost effectiveness. 
5.1.2 Design 
The overall design is a pragmatic cluster randomised controlled trial comparing a new approach to 
the management of multimorbidity in general practice versus usual care, with process evaluation 
and economic analysis of cost-effectiveness.  
In line with the MRC framework for the evaluation of complex interventions [39], we will first 
conduct a pilot and optimisation phase and then conduct a parallel mixed methods process 
evaluation alongside the trial to examine how the intervention is implemented by intervention 
practices and to characterise usual care. This will help to gain understanding about why the 
intervention worked (or did not work), and will inform and facilitate commissioning and other 
implementation of the intervention if appropriate.  
Economic evaluation will be undertaken from the perspectives of (a) NHS and personal social 
services (PSS) and (b) patients. In a cost-consequences analysis we will relate the cost of the 
intervention or usual care to changes in a range of outcomes; cost-effectiveness analysis from the 
NHS and PSS perspective will estimate the incremental cost per QALY gain. 
5.1.3 Theoretical/Conceptual Framework 
18 
 
The underlying theoretical basis for the intervention is the Patient Centred Care Model, described by 
Stewart et al [40]. This is strongly valued by patients[41] and there is some evidence that it is 
associated with improved health outcomes [42-45]. A recent report from the American Geriatric 
Society has recommended the Patient Centred Care Model to improve care for multimorbidity [31]. 
The concept of patient centred care has been reviewed and developed by later authors [46,47] but it 
broadly includes four key components: 
 A focus on the patient’s individual disease and illness experience: exploring the main reasons for 
their visit, their concerns and need for information. 
 A biopsychosocial perspective: seeking an integrated understanding of the whole person, 
including their emotional needs and life issues. 
 Finding common ground on what the problem is and mutually agreeing management plans. 
 Enhancing the continuing relationship between the patient and doctor (the therapeutic 
alliance). 
As shown in the flow diagram in Appendix C, the conceptual framework for our intervention draws 
on the existing research evidence about the main types of problems experienced by patients with 
multimorbidity and their preferences for care, and uses strategies based on the Patient Centred Care 
Model to seek to address these problems. For example, there is evidence that patients with long 
term conditions particularly value relational continuity of care[48], therefore the intervention 
includes strategies to improve relational continuity and one of the outcome measures (CARE) 
collects data about whether this is achieved.  
Our conceptual framework also draws on the Chronic Care model[49] and experience in related 
initiatives such as Year of Care [50], for example the importance of promoting patient engagement 
in self-care through care plans, improving communication between primary and secondary care, and 
the recognition that organisational change needs to be accompanied by attitudinal change amongst 
clinicians, enhanced by training, appointment of local GP champions, collaborative working, 
incentives, support and feedback. 
5.2 Study setting 
This study is based in primary care involving General Practices serving different patient populations 
in 3 geographical areas; in and around Bristol, Manchester and Glasgow. Practices will be selected 
from areas within a range of socioeconomic deprivation levels as well as urban, suburban and rural 
areas. 
5.3 Eligibility criteria for Practices 
General practices with the following criteria will be approached: 
 A minimum of three GP partners 
 Minimum practice list size of 4,500 patients 
 Uses EMIS GP computer system 
 
5.4 Eligibility criteria for participants 
5.4.1 Inclusion Criteria 
 Aged 18 and over (on date of invitation to participate) 
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 Three or more long term conditions from the following list of conditions: 
 Cardiovascular disease (CVD) or Chronic kidney disease (CKD): including coronary 
heart disease, hypertension, heart failure, peripheral arterial disease, chronic kidney 
disease stage 3 to 5. 
 Stroke 
 Diabetes 
 COPD or asthma 
 Epilepsy 
 Atrial fibrillation 
 Severe mental health problems (eg. Schizophrenia, psychotic illnesses) 
 Depression 
 Dementia 
 Learning disability 
 Rheumatoid arthritis 
In the above list we have grouped a number of cardiovascular conditions together, along with CKD, 
as management of them is very similar, and similarly grouped asthma and COPD together. Therefore 
these only count for one disease if patients are coded with more than one disease within these 
categories. 
The research team will maintain awareness over developments concerning updates to QOF clinical 
indicators and any changes to the QOF list will be reflected in the inclusion criteria for the study. 
The 2015/16 QOF rules have removed osteoporosis and Chronic kidney disease from the disease list. 
However, given that the management of CKD is similar to the management of hypertension, it is 
clinically appropriate to still include CKD as an inclusion criteria, but to include this as counting 
towards one disease condition of ‘CVD or CKD’ as a single entity. 
5.4.2 Exclusion Criteria 
In order to maximise generalizability of this intervention, the exclusion criteria have been kept to a 
minimum. These patients are often excluded from other research and it is these patients with the 
greatest burden of illness that have the most to gain from this intervention. Therefore the very 
elderly, patients in nursing homes or housebound, those with mental health problems and those 
with multiple comorbidities, are all included. 
In England only, where patients lack capacity, we will seek consent from their legal guardians or 
consultees. The Scotland A REC board ruled that under Scottish Law, adults who lack capacity to 
consent should not be included in research studies if not essential. Therefore for practices in 
Scotland only, adults lacking capacity to consent will be excluded. If participants are unable to 
complete questionnaires themselves, carers can do so on their behalf. We will undertake sensitivity 
analysis of the impact of including or excluding responses provided by carers on the main results. 
Patients who will be excluded: 
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 Life expectancy of less than 12 months  
 Serious suicidal risk 
 Known to be leaving practice within 12 months 
 Cannot complete questionnaires in English (themselves or with the help of carers, which 
may include excluding those with visual or hearing impairment) 
 If actively taking part in other research involving extra visits to GP or other health 
services. 
 Adults lacking capacity to consent (Scotland only) 
 
5.5 Recruitment procedures 
5.5.1 Recruitment of General Practices 
Local contacts from the Clinical Research Networks (CRN), Primary care and Scottish Primary Care 
Network will be approached to assist in identifying and accessing GP practices who are interested in 
taking part in the trial.  
Interested practices will be contacted by local researchers who will arrange a meeting(s) with the 
practice manager, GP partners and practice nurse(s). It is important to get the acceptance and 
understanding of all the key stakeholders at the practice since the study involves randomisation at 
the practice level, which therefore requires a commitment to organisational and procedural change. 
Practice representatives will be asked to sign a practice agreement consenting to the practice taking 
part in the study. 
Since this is a cluster randomised trial, all eligible patients within one practice will be treated in the 
same way, subject to their consent. Patients will be asked to give consent to being offered care 
based on the new 3D approach, if their practice is allocated to the intervention arm, and also to 
complete questionnaires and to allow researchers access to their medical records. 
We plan to recruit 32 practices for the main trial: 12 near Glasgow, 10 near Bristol and 10 near 
Manchester. However we will seek to recruit at least two more practices in each of these areas to 
act as ‘reserves’ in case a practice drops out after initially agreeing to take part. In this way we can 
ensure that practices are blind to which arm of the trial they will be in at the time they are recruited. 
5.5.2 Identification and consent of patients 
General practices agreeing to participate in the study will be asked to search their practice database 
using an electronic search strategy devised by the research team based on pre-defined Read-Codes 
to identify potentially eligible patients who have three or more long term conditions as defined 
above. GPs will be given the opportunity to screen the resultant list for the above exclusion criteria. 
The practice will then send out patient invitation packs which will contain an invitation letter from 
the GP, a patient information sheet explaining about the study, an acceptance/consent form, a 
baseline questionnaire, and a freepost envelope. Patients will be asked to respond by returning the 
consent form and completed baseline questionnaire to the research team, using the freepost 
envelope. Patients who do not wish to participate will be invited to return a blank questionnaire. 
21 
 
Practice staff will also send one postal reminder to individuals who have not responded 
approximately 10 days after the initial mailing. This may be supplemented with a telephone 
reminder by a member of practice staff or a researcher with an honorary contract acting on behalf of 
the practice if necessary. 
Maximum statistical efficiency within a cluster trial is achieved if all clusters are of equal size; large 
variation in the number of patients participating across practices will therefore reduce the power of 
the trial. For this reason the maximum number of patients within a practice invited to participate will 
be restricted. This will also reduce the burden on larger practices of potentially having to re-organise 
care for a large number of patients, and hence limit the cost of the study. The sample size calculation 
estimated the average number of eligible patients to be invited per practice to be 108 (see section 
5.1). We will initially select a maximum of 150 patients in each practice, randomly selecting those to 
invite from all potentially eligible patients. After GPs have screened and excluded further ineligible 
patients we anticipate that we will invite up to about 130 patients in larger practices, with the aim of 
recruiting about 43 patients per practice. These numbers are provisional and may be modified in the 
light of our experience about the number of potentially eligible patients and the proportion that 
return questionnaires. Those patients who provide consent to participate in the study form the 
group of patients who will receive the intervention in the intervention arm practices. If patients wish 
to talk to someone about the study, they can contact a research contact at their GP practice or a 
member of the local research team whose details are on the patient information sheet and 
invitation letter.  
This is an individual-cluster trial where the unit of experimentation and the unit of observation is at 
the level of the individual. Therefore individual level consent is sought to participate in the study, to 
complete questionnaires and to allow the research team to collect relevant information from their 
medical notes. 
 
5.5.3 Permission of Patient’s Carers 
We are also interested in the views and experiences of carers. Therefore as part of the invitation 
pack to patients, we will also include a form for carers requesting contact details, permission to 
contact them and consent to complete a separate carers questionnaire at baseline, 6 months and 12 
months. 
If the GP assesses that a patient lacks capacity to consent, in England, we will obtain the assent of 
the patient’s carer, legal guardian or consultee on behalf of the patient for them to take part in the 
study. 
5.5.4 Baseline data collection 
Participants will be sent a postal baseline questionnaire as part of the invitation mailing. The 
questionnaire will include questions on socio-demographic factors (age, gender, ethnicity, marital 
status, work status and deprivation status (via postcode) and details of health conditions) as well as 
baseline measures for all study outcomes. Personal ID and contact details will also be elicited so that 
the research team can acknowledge receipt of completed questionnaires and provide a £5 gift token 
in appreciation of the patient’s help. 
On receipt of a completed questionnaire, the researcher will mail a letter confirming receipt and a 
£5 gift token in appreciation of the patient’s help. This will be followed this up 1 week later with a 
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telephone call from the local research team to confirm receipt of the letter and voucher and to 
provide an opportunity for any questions from the participant. 
 
5.6 Randomisation 
GP practices will be the unit of allocation. Practices will be randomised using an automated web 
randomisation system run from the Bristol Randomised Trials Collaboration (BRTC, UKCRC 
registration ID: 2) on a 1:1 ratio to receive either the intervention or continue care as usual (control 
group). Randomisation will be stratified by area (Bristol, Manchester, Glasgow) and minimised by 
deprivation level and practice size.  
In order to minimise post-randomisation selection bias, practices will not be randomised until after 
patients have been identified and after the initial patient invitations have been mailed. 
5.6.1 Control group 
Practices allocated to the control arm will continue care as usual. In most practices this will mean 
patients are recalled to different clinics to see different practice nurses to review each of their long 
term conditions. The nurses will usually follow disease specific computerised protocols for their 
management, and will mainly focus on collecting data related to QOF targets rather than quality of 
life or patients’ priorities. 
5.6.2 Blinding 
Is it not possible to mask participants or health care professionals to the group allocation of their 
practice. It is also not feasible to blind all members of the study team actively involved in the 
execution of the study. However, as far as possible, analysis of outcomes will be performed blind.  
5.7 Procedure optimisation and pilot 
Prior to commencing the main trial in 32 practices we will recruit 3 practices (2 in Bristol and 1 in 
Manchester) and will use this to optimise the intervention and pilot procedures for the trial. We will 
implement the intervention as described in all 3 practices. Through direct observation of the training 
events, observation of some 3D patient reviews and interviews with a sample of patients, GPs, 
practice nurses, receptionists and practice managers we will seek to improve the training 
programme, learn from stakeholders about how the intervention can be improved, refine the 
intervention to improve the likelihood of it being implemented as planned in the main trial, and 
ensure that the IT infrastructure (computerised search routines and new 3D data collection 
template) works smoothly in a range of practices. This phase will also enable us to pilot aspects of 
the trial, including checking that our estimates about the recruitment rate are reasonable, test our 
patient documentation, pilot data collection mechanisms, and assess follow-up rates. Although the 
main trial will have started before the patients in pilot practices complete the 6 month follow-up 
measures, there will be an opportunity to improve follow-up procedures for the main trial because 
of the time lag between pilot and main trial practices. 
5.8 Follow-up procedures 
Follow-up data will be collected at 6 and 12 months post randomisation with the primary outcome 
time-point being at 12 months. The primary method of self-reported data collection will be via 
postal questionnaires, however alternative completion methods including online, phone or via a 
home visit will be offered in order to maximise response rates.  
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Prior to being sent follow-up questionnaires, the research team will attempt to telephone or email 
participants to pre-notify them. This is particularly important for those participants reliant on 
carers/guardians or representatives, if they lack capacity or require help completing the 
questionnaires. It provides the opportunity for participants to ask questions, remind participants 
that they are taking part in research (e.g. if they are in a control practice group) and pre-notification 
has been shown to improve response rates [51]. 
Two reminders, the first by letter or e-mail (approximately 10-14 days after posting the 
questionnaire) and the second by phone (approximately 10-14 days after the first reminder), will be 
conducted for participants who have not returned their questionnaire. 
Patients will be given £5 gift vouchers for completion of questionnaires. However, the research team 
would like the option of performing a sub-study examining the timing of providing vouchers pre- and 
post questionnaire completion. We envisage submitting this substudy as a substantial amendment 
to the protocol for REC approval at a later date. 
 
5.9 Withdrawal 
5.9.1 Practice Withdrawal 
A practice can decline to take part at any time during the initiation and set-up phase of practice 
recruitment.  
Once a practice has been randomised, they may withdraw from the study only under extreme 
circumstances. If a practice wishes to withdraw the situation should be discussed with the local 
team, TMG members and CI. All avenues should be explored to try to resolve the problems and 
concerns of the practice.  
If a practice must be withdrawn, then time permitting an additional site will be allocated to the same 
randomisation group from the ’reserve’ practices originally recruited. The new site will be from the 
same area (Bristol, Manchester, Glasgow) and if possible the same deprivation level (high/low) and 
practice size (small/large). If there is more than one feasible practice, the replacement practice will 
be randomly selected.  
If a practice must be withdrawn after having signed the study agreement and after their patients 
have given consent to participate, we will still seek to obtain outcome data on the practice’s patients 
if at all possible. It is likely that withdrawal will be due to practice difficulties in delivering the 
intervention rather than an unwillingness to allow us to collect data from their patients’ records.  
Any practice withdrawing, which is replaced, will not be included in the primary intention to treat 
analysis, but will be included in sensitivity analyses if outcome data are available. 
5.9.2 Participant withdrawal 
If the participant has already consented, but later decides to drop out, they have several options:  
a) Withdrawing from just the data collection (i.e. completing questionnaires and/or allowing 
researchers to access their medical records), whilst still continuing to receive the 
intervention if their practice is in the intervention arm. 
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b) Withdrawing from receiving the intervention from their practice, if their practice is in the 
intervention arm, but still completing the data collection 
c) Withdrawing from both data collection and intervention if their practice is in the 
intervention arm. 
Any data collected from the patient prior to withdrawal will still be included in the final analysis of 
the data. Withdrawal from the study does not affect the patients’ treatment or access to NHS 
services.  
A notification of withdrawal can be directly from the patient, their carer, GP, or other practice staff. 
On receipt of such notification, a member of the research team will contact the patients to confirm 
the request and explain the withdrawal options.  
Patients do not have to give a reason for withdrawal if they choose not to although possible reasons 
could include being too busy, or does not wish to complete any more questionnaires. If the 
withdrawal is due to the participant experiencing an adverse event, a worsening of their symptoms 
or has died, the researcher will follow the standard operating procedures (SOP) for adverse events in 
addition to the withdrawal SOP. 
This information will be passed onto the participants’ GP in order for their records to be updated.  
 
6 Intervention 
 
This is a complex intervention, with four main components: 
1) Identification and prioritisation of patients with multimorbidity: These patients will be 
identified on practice database systems and ‘flagged’ in order to prioritise them for a different 
model of care. These patients will also be provided with a ‘3D’ card in order to identify them with 
practice staff (see below). 
2) Improving patient-centred care: Patients will be prioritised for enhanced continuity of care. 
Each patient will be allocated a named usual GP and usual practice nurse, who will be identified in 
the patient’s notes and between them will have responsibility for co-ordinating their care. Patients 
will identify their 3D status to receptionists when booking appointments and will be offered longer 
appointments with their usual doctor or nurse whenever possible. Other elements of the review of 
their long term conditions described below (for example the emphasis on care planning) will also 
enhance patient centred care. 
3) Reducing the burden of illness and treatment: ‘3D’ patients will be offered a comprehensive 
assessment every 6 months, instead of separate reviews for each of their LTCs. Each 3D assessment 
consists of two appointments a week apart, the first with the patient’s usual nurse and the second 
with their usual doctor. Both will follow the same ‘3D’ assessment structure, supported by a bespoke 
computerised template: 
DIMENSIONS of health. First elicit patients’ concerns and priorities for improving their quality of life 
(e.g.mobility, pain) before collecting data about disease based indicators e.g. weight, BP. 
DEPRESSION. The template will include questions to identify depression (PHQ9). 
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DRUGS. Before the baseline assessment, a pharmacist will review the patient’s medication list to try 
to identify ways to simplify the patient’s drug regime, potentially unsafe drug combinations, drugs 
which are indicated according to guidelines but are not being prescribed, and drugs which may be 
indicated but are potentially inappropriate or are low priority for this patient in view of their 
comorbidities. They will be supported in this by computerised ‘rules’ applied to the patient’s 
electronic medical record. A note of the pharmacist’s recommendations will appear in the 3D review 
template, for consideration by the GP. This pharmacist review will occur once a year i.e. at alternate 
3D reviews. In addition, the template will prompt the nurse and GP to check at every 3D review 
whether patients are taking the drugs they have been prescribed, using questions designed to detect 
problems with adherence, and whether they understand what the drugs are for. 
At the first 30 minute appointment, the practice nurse will collect information to complete the 
template and organise all relevant blood tests/investigations. Following the nurse appointment the 
patient will be given a letter summarising their assessment which details their top priorities for 
change. This will set the agenda for the second appointment, approximately one week later, with the 
patient’s usual GP. At this 20 minute appointment the GP will review all the information collected by 
the nurse and from the test results, undertake a through medication review with the help of the 
pharmacist’s recommendations, use evidence based strategies to address the patient’s priorities and 
problems identified in the assessment, and agree a written care plan for the patient to take away. 
For example, if depression was identified, treatment will be based on stepped care to 
antidepressants and/or psychological intervention according to severity [52]. An important focus of 
the GP appointment will be evidence-based approaches to simplifying medication regimes, stopping 
high risk or low priority drugs and promoting medication adherence [53,54]. Doctors will be trained 
in these strategies and will be guided by the pharmacist’s recommendations [55].  
Following the 3D review, follow-up will be determined by the patient’s needs and plan. 
4) Improving integration. Each practice will have a designated ‘general physician’ whom they can 
contact to discuss individuals with complex problems,[56] and to help co-ordinate use of hospital 
investigations and appointments where patients are attending numerous different specialist clinics 
or having multiple hospital based tests on different days. 
 
Supporting practices to provide the intervention 
Working with commissioners, we will use financial incentives to encourage clinicians to attend 
training and complete 3D assessments, as if the intervention was included in a Local Enhanced 
Scheme[57] or part of the QOF.  
We will provide training to help practices to implement the intervention as intended. All GPs and all 
practice nurses involved in LTC management will be asked to attend two half days of training, with 
practices training together to share ideas. Practice nurses and GPs will be trained to use the 3D 
assessment template, to focus on addressing issues relating to quality of life, depression, and 
medication adherence as well as disease management, and how to create a written care plan with 
the patient. A substantial element of the training will be devoted to promoting attitudinal change 
amongst clinicians towards identifying and responding to patients’ own priorities and problems with 
broader quality of life, as organisational change is unlikely to be effective unless clinicians ‘buy into’ 
the underlying philosophy of the new approach [50].  
Following initial training, we will appoint a local GP champion in each practice to monitor and 
maintain adherence with the intervention amongst practice staff and to promote the research. GP 
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champions from intervention practices in each area will meet together in local collaboratives to 
share good ideas and experiences. We will allow local adaptation of the intervention to reflect local 
context while ensuring the key elements of the conceptual framework are maintained.[58] We will 
provide regular feedback about implementation e.g. the number of patients who have had a 3D 
assessment (which we will monitor through regular searches in the intervention practices, with the 
help of practice champions).  
GP Receptionists will be offered training at their own practice. Receptionists will have a key role in 
ensuring that patients are offered longer appointments with their usual nurse or GP. They will be 
trained in strategies and forms of words to achieve this.  
7 Data Collection 
 
Participant study data will primarily comprise of self-reported questionnaires and GP patient 
records. Research teams at each site will be responsible for data collection including sending the 
questionnaires, collating, logging the data and entering the data onto the trial database and 
collecting data from GP records. Letter and email reminders will be sent to participants who do not 
return questionnaires within 14 days. Participants may receive a further phone reminder or may be 
called if the primary outcome is incomplete. 
7.1 Quantitative Outcome Measures 
All outcomes are at the level of the individual patient and will be collected at baseline, 6 months and 
12 months post randomisation. 
7.1.1 Primary Outcome 
The primary outcome is health related quality of life, measured using the EQ-5D-5L [59] at 12 
months. This is a self-report measure which will be collected by paper questionnaires. 
7.1.2 Secondary Outcomes 
These patient reported outcome measures will be collected at baseline and 6 and 12 months post 
randomisation from patient questionnaires.  
Burden of illness measures to assess quality of life, disease control and depression: 
 Self-rated health (single item) 
 Bayliss measure of illness burden in multimorbidity [60] 
 Quality of disease management (composite measure of QOF achievement) [61] 
 Hospital Anxiety Depression Scale (HADS) [62] 
Burden of Treatment measures to assess the problems of poor coordination of care, multiple 
appointments and polypharmacy: 
 Brief Treatment Burden Questionnaire 
 Morisky Medication Adherence Scale (8 item) [64] 
 Number of drugs prescribed 
27 
 
 Reduction in high risk drug combinations[65] 
Experience of patient centred care, to assess the lack of holistic patient centred care: 
 CARE measure and how well you know your doctor[66] 
 Coordination of care and care related to patient’s priorities (questions from LTC6 QIPP) 
 Management of LTCs (PACIC) [67] 
 Overall satisfaction (single item) 
7.1.3 Socio-demographic measures 
The following socio-demographic measures will be collected from self-reported paper 
questionnaires at the baseline timepoint only (prior to GP practice randomisation). These measures 
will allow comparison of population composition between study groups and study centres, and will 
also be used for subgroup analyses. 
 Number of long term conditions 
 Age (on date of invitation to participate) 
 Gender 
 Education 
 Ethnicity 
 Deprivation status – based on postcode which maps onto the index of multiple 
deprivation. 
 Work status 
7.1.4 Carer outcomes 
The role of the carer in supporting a patient with multimorbidity is often neglected. In order to 
assess whether the change in GP management affects other aspects of the participant’s care we 
request that the participant’s carer also complete questionnaires about their experience and how it 
affects their wellbeing. Carer contact details and consent to complete brief surveys will be requested 
in a form which will be included as part of the initial patient invitation mailing pack. Carers will be 
requested to complete the survey at baseline, 6 and 12 months follow up. 
Measures of strain on patient’s carers: 
 Carer Experience Scale [68] 
 EQ-5D-5L [59] completed by carers 
 Brief Treatment Burden Questionnaire for carers 
 
7.1.5 Resource use 
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Resource use will be compiled from a combination of self-report measures in participants’ follow up 
questionnaires at 6 and 12 months and electronic GP records examined at the end of the study. 
Participants will be asked to provide information concerning:  
 Hospital admission and outpatient attendance. 
 Use of health services in primary, community and secondary care 
To simplify data collection, the questionnaires will ask whether participants have been admitted to 
hospital. If so, the researcher may phone the participant to obtain more detailed information about 
reason, length and place of stay if the information is not available in their GP notes.  
GP records will confirm participants’ resource use over the course of the 12 months that they were 
in the study. Researchers will request access to patients’ records after 12 month follow-up data 
collection has been completed. In addition to the above data, the following information will be 
collected from GP records: 
 Any health investigations the participant underwent 
 All medications prescribed for the patient over the course of the study 
Resource use information is required for the economic evaluation of the service. It is also a way of 
demonstrating changes in the process of care. 
 
7.2 Data Management 
7.2.1 Source data 
Data will primarily be in the form of participant self-report paper questionnaires, logs collated from 
GP/nurse 3D computer template usage, extractions from patient records and case report forms. 
Research teams at each recruitment site will be largely responsible for the collection and monitoring 
of data from participants and practices within their areas. Overall responsibility of the study data will 
be with the Chief Investigator which can be delegated to the Trial Manager and Data Manager. 
Patient, carer and practice staff contact details needed for day-to-day trial management will be held 
on a bespoke management database, designed and managed by the BRCT and held on secure 
servers at the University of Bristol. Since ID numbers will be accessible from this system, researchers 
will have unique logins and restricted access to the appropriate recruiting centre data only. 
All paper questionnaires and records will be entered into a separate tailor-made database held on a 
central university server. The data is entered via a securely authenticated, web-based, commercial 
software system called REDCap. This database will only store anonymised questionnaire and CRF 
data. Study researchers will be given a unique login in order to access and input on this database. At 
least 10% of questionnaire data from each site will be subject to double entry and second checking 
to ensure quality and inter-rater reliability. 
Qualitative data collection will be conducted and analysed by the qualitative researcher (CM) and 
will involve a variety of mixed media. Full details are provided in the Process Evaluation section of 
this document (section 7.6)  
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In accordance with REC requirements, regulatory authorities including monitors and auditors from 
NHS Trusts may request access to source data and documents for cross checking. This will be 
explained in the participant information sheet and a statement included as part of the written 
consent form to be signed by the participant. 
7.2.2 Data Storage 
Where possible, personal identifiable details will be removed from hard-copy documents and 
replaced with the participant’s unique trial identification number. During the study, all hard copy 
documents containing patient identifiable data (e.g. consent forms) will be stored in (as a minimum) 
locked filing cabinets within alarmed, access restricted University buildings of each of the research 
centres. Only local research teams will have access to these locked cabinets. 
Electronic data will only be accessible via a password protected database held on a secure server. 
See section 11.3 for long term storage procedures at the end of the study. 
8 Data Analysis of quantitative trial outcomes 
8.1 Sample Size calculation 
The study is designed to detect an effect size of 0.274 standard deviations in the primary outcome of 
the EQ5D-5L. Data about the variability of the new 5 level (5L) version of the EQ5D is currently more 
limited than for the well-established 3 level (3L) version. The standard deviation of the EQ5D-3L in 
the UK general population is 0.23, rising to 0.27 in the oldest respondents (aged over 75).[69]Hence 
an effect size of 0.274 would equate to a detectable difference of (0.274*0.27) = 0.074 on the EQ5D-
3L, previously deemed to be the minimum important difference.[70] Although there are less data 
about the variability in the 5L version of the EQ5D than the 3L version, it seems wise to use this 
latest version of the EQ5D as it is likely to have greater sensitivity to change.  
Based on data available from our previous studies, we estimate that 2.3% of adult patients will have 
multimorbidity in terms of 3 or more LTCs as defined in this study. This equates to about 108 
patients in an average sized practice of 6000 patients i.e. 3456 potentially eligible patients in 32 
practices. Assuming 40% of patients agree to participate (n=1382), 80% are followed up to 12 
months, and an ICC of 0.03 for clustering at the practice level (based on the WISE trial)[31] this 
sample provides around 90% power at a 5% significance level to detect an effect size of 0.274 
standard deviations in the EQ5-D measure between the intervention and control groups. This is 
considered a small effect size. 
In practices with large numbers of potentially eligible patients we will randomly select a maximum of 
150 potential participants, as described in section 2.5.2. After GPs have excluded ineligible patients 
we anticipate inviting about 110 patients per practice, on average. The number of patients initially 
selected will be reviewed following the optimisation phase 
 
Efficacy data analysis 
Data will be analysed in accordance with CONSORT principles and its extension for cluster 
randomised trials. Descriptive statistics will be used to summarise characteristics of both practice 
and patients and compare the balance across groups. We will take account of clustering by practice 
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in all analyses using multi-level regression models. A full statistical analysis plan will be developed 
and agreed by the Data Monitoring Committee (DMC) and Trial Steering Committee (TSC) after the 
pilot phase and prior to undertaking any analyses of the main trial. 
8.1.1 Primary analysis 
Intention to treat analysis will compare groups using a linear multi-level regression model adjusted 
for baseline values, stratification/minimisation variables, clustering and other important co-variates 
such as age, number of long-term conditions, deprivation, depression. The results will be presented 
as the difference between group means and corresponding 95% confidence intervals will be derived. 
8.1.2 Secondary and subgroup analysis 
Multi-level regression models will be applied to evaluate differences between groups for the pre-
planned analyses of secondary variables. These will be based on logistic or linear regression as 
appropriate.  
We will use sensitivity analysis to examine the effect of missing data on outcomes based on different 
assumptions. We will conduct subgroup analyses using appropriate interactions terms to explore the 
effectiveness of the intervention in relation to age, number of long term conditions, index of 
deprivation and presence or absence of depression alongside physical health problems. These 
subgroup analyses will be hypothesis generating and will focus on interpretation of 95% confidence 
intervals rather than P-values. Subgroup analyses are likely to be insufficiently powered since the 
trial was not powered to specifically test these effects. 
8.1.3 Use of anonymised data 
Anonymised data will be used for the following: 
i) Comparison of descriptive data for consenting vs. non-consenting patients 
ii) Comparison of QOF performance in patient with LTCs with and without 
multimorbidity. This is to assess for any unintended consequences, ie. whether 
concentrating effort on patients with multimorbidity has any positive or negative 
impact on the care of other patients. 
iii) iii) Comparison of hospital admissions and deaths. We will explore the feasibility of 
obtaining data via anonymised records linkage (HES data and death registry) in order 
to examine the impact of the intervention on all eligible patients in participating 
practices, and also to compare the impact on patients with or without 
multimorbidity, without needing individual patient consent or access to identifiable 
patient data. Without these data, we will only be able to collect this information for 
patients who return questionnaires, and this analysis would lack power since the 
events (particularly deaths) are relatively rare. 
9 Economic Evaluation 
Economic analysis will be undertaken from the perspectives of: 
a) NHS and personal social services (PSS) 
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b) Patients 
We will also measure and value the time off work and usual activities. 
Resource use data will be collected from self-reported patient questionnaires from questions of 
utilisation of primary, community and secondary care services and personal costs (including travel, 
loss of earnings and dependent care costs). These data will be supplemented by GP records and trial 
records where appropriate. Unit costs will be valued using national published sources such as Curtis 
[71] , NHS reference costs and the British National Formulary (BNF).  
The set-up and training costs of the intervention will be identified and estimated separately from the 
running costs. The costs of each component of the intervention will also be estimated separately 
from each perspective and when related to changes in a range of outcomes will give the cost 
consequences.  
Cost effectiveness analysis from the NHS and PSS perspective will estimate the incremental cost per 
Quality Adjusted Life Year (QALY) gain. A QALY  is a composite measure of health combining quantity 
and quality of life. QALYs will be estimated using the EQ-5D-5L. 
Uncertainty will be addressed in sensitivity analyses and by using bootstrapping to estimate the net 
monetary benefit and a cost-effectiveness acceptability curve. 
10 Process Evaluation 
10.1 Background 
Process evaluations of complex intervention trials are recommended by the MRC Framework [39] 
and have many potential purposes [72], but there is relatively little guidance on how best to design 
them. One of the applicants has recently published a framework for process evaluation design which 
emphasises the importance of explicitly stating the aims of the evaluation and the choice of 
processes to examine [72]. The aims of the mixed methods process evaluation in this project are: 
 If the intervention is effective, to identify and document examples of good practice and 
strategies for successful implementation, and also practical difficulties in implementation 
and maintenance, in order to inform commissioning and other long-term implementation. 
 If the intervention is ineffective, to identify if this is due to problems with the intervention 
(failure of intervention concept despite the intervention being delivered as intended) or 
problems with intervention delivery (implementation failure, which may occur at multiple 
points) [73]. 
The process evaluation will therefore explore issues of representativeness, intervention 
implementation, reach at patient level, nature and fidelity of intervention delivery, maintenance of 
the intervention over time, and patient perceptions of how care has changed. This will help to gain 
understanding about why the intervention worked (or did not work), and will inform and facilitate 
commissioning and other implementation of the intervention if appropriate. 
The process evaluation will also include practices in the usual care group, in order to clarify what are 
the current practices in the management of multimorbidity patients. Given the recent changes in the 
NHS and GP contracts and structures, it is necessary to characterise what usual care is at the start of 
the trial and whether this changes over the intervention period so that we define what we are 
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comparing the intervention to. This can also help to inform of ways of future delivery of the 
intervention.  
10.2 Design 
The process evaluation will be mixed methods, combining analysis of quantitative process data (such 
as patient characteristics, number of consultations, number of drugs prescribed) from all practices 
with an in-depth, comparative case study [74] in up to five purposively selected intervention 
practices, chosen to represent those in different settings and with different prior levels of 
organisation of care for patients with LTCs. Data will be  supplemented by interviews with 
commissioners.  
There will be an optimisation study preceding the process evaluation of the main trial. The aim of 
the optimisation study is to help the main trial team optimise the intervention. This will be achieved 
by evaluating implementation of the different elements of the intervention to identify any 
implementation problems or divergence from the intentions of the trial. It will also allow the process 
evaluation methods to be used in the main trial to be piloted and evaluated. The methods will be as 
described below for the main trial but in smaller numbers i.e. 2 case study practices and some 
supplementary interviews and observations in the other 2 pilot practices 
10.3 Methods and Setting 
Up to five purposively selected case study practices will be chosen, to represent different settings 
and with different prior levels of organisation of care for patients with LTCs. Additional data 
regarding some processes may be collected from other practices participating in the 3D trial 
depending on fidelity and implementation issues identified during the course of the process 
evaluation. Information regarding usual care will be collected from all practices at the start of the 
trial and at the end of the intervention period, by questionnaire supplemented by interview if 
necessary. 
Quantitative methods will involve the analysis of routinely available data on practice characteristics 
and data collected as part of the trial. 
Qualitative methods will involve semi-structured interviews, focus groups and direct observation of 
these case study practices. If necessary, qualitative data will be collected from some other practices 
taking part in the 3D trial in response to particular issues that arise during the trial. These methods 
are described in detail below. 
10.4 Sampling 
Practices: Up to 5 study practices will be purposively selected to take into account geographical 
region, socioeconomic deprivation levels and different prior levels of organisation of care for 
patients with LTCs. Practices will be the main unit of sampling and within these case practices, we 
will sample a range of people (patients and staff) and events (consultations, appointment bookings) 
over a period of 12 months.  
Practice staff: We will undertake approximately 40 interviews sampled purposively to reflect a range 
of relevant professionals including receptionists, practice nurses, GPs and Practice Managers. These 
will mainly be in the case study practices but may also include some interviewees from other 
practices taking part in the 3D trial. 
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Patients: Approximately 6 patients per case study practice and some from other practices 
participating in the trial (n= 30 total approx.), will be purposively sampled for heterogeneity in age, 
sex, socio-economic status and LTCs. 
10.5 Recruitment 
Staff: We will write to practice staff in case study practices and some other participating practices 
asking for consent to participate in an interview, and in some cases, to participate in recording and 
observation of a consultation with a patient. We will include an information sheet and consent form.     
Patients: When consenting to participate in the trial, participants will be asked if they are willing to 
be approached by a member of the research team at a later stage to consider taking part in an 
individual or focus group interview and in the observation and recording of a consultation. If they 
agree, we will write to them with an information sheet and relevant consent form if they are 
sampled for interview.   
10.6 Data Collection for Process evaluation 
10.6.1 Quantitative data 
Quantitative data on practice recruitment and representativeness, reach at patient level (whether or 
not patients receive the intervention), implementation of intervention elements and whether or not 
the actual process of care is different from usual care from the patient’s perspective will be gathered 
as part of the main trial data collection (Box 1). Data on recruitment will be used to examine 
representativeness of participating practices to inform judgements about generalisability. 
Box 1 Process evaluation quantitative questions and methods 
PROCESS: RESEARCH QUESTION DATA COLLECTION 
Recruitment: How representative 
are recruited practices? 
Analysis of routinely available quantitative data on practice 
characteristics (comparing characteristics of recruited and non-
recruited practices) 
Reach at patient level: What 
proportion of targeted patients 
receive the intended assessment? 
Analysis of quantitative data collected as part of trial (for practices in 
the intervention arm):  
Number of patients given a 3D card, receiving a comprehensive 3D 
assessment and components of this (e.g. quality of life discussion, 
mental health assessment, care plan, treatment for depression). 
Evidence of intended changes in 
care. Is the process of care in 
intervention practices different 
from that in control practices?  
Analysis of quantitative data collected as part of the trial (comparing 
practices in the intervention and control arms) e.g. number of 
appointments per patient; Continuity of care (COC measure of 
longitudinal continuity [75]); Number of contacts with hospital 
general physician; provision of pharmacy advice, number of drugs 
prescribed. 
 
10.6.2 Qualitative data 
We will collect qualitative data in the following ways see Box 2. 
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1. Observation/recording of training sessions for intervention practices 
2. Interviews and focus groups involving patients/carers 
3. Observation of practice setting and reception 
4. Observation/recording of 3D consultations 
5. Interviews with practice staff 
Semi structured interviews of lead GPs and practice managers will occur at two time-points 
(approximate total n=20 interviews). 
i) Early in the implementation, approximately 4 weeks after initial training to reveal whether 
and how practices plan to reorganise care to deliver the different elements of the 
intervention. 
ii) Towards the end of the trial in order to elucidate whether and how practices maintain the 
reach and fidelity of the intervention over time. In addition what where the barriers and 
facilitators of successful maintenance? 
 
Additional practice staff including receptionist, practice nurses and GPs (will also undergo semi 
structured interviews at 2 time points (approximate total n = 20). 
i) Soon after initial training to appraise care at baseline and to evaluate the adequacy of the 
training and attitudes towards the change in care processes 
ii) After 3D reviews have been begun to appraise how the intervention was delivered in the 
practice and how it affected their individual roles. For nurses and GPs, also to evaluate a 
recently recorded 3D review  
 
Approximately 6 patients per case study practice and some from other participating practices 
(approximate total n = 30) will be invited to one focus group per practice before the intervention to 
assess how they perceive existing care. After the intervention has been implemented, they will 
undergo a semi-structured interview, which may be after a recorded consultation to assess how 
patients perceive the changes in their care and to evaluate a recently recorded consultation. These 
interviews will be conducted at a time and place agreed by the participant and can include the 
patient’s home or University building. At the end of the interview, participants will be offered a £5 
gift voucher as a goodwill gesture for their time. 
Non-participant observation of the training delivered to practices and completion of evaluation 
forms by participants and trainers will assess the response of practice staff to the intervention and 
the adequacy of the training. 
Non-participant observation of appointment booking at the reception desk and by telephone will 
examine if and how the appointment system has been reorganised for participating patients. 
A sample of 3D assessment appointments in case study practices and some in other intervention 
practices (approximate total n=20) will be audio or video recorded and/or observed to evaluate the 
nature and fidelity of this aspect of intervention delivery. 
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Box 2 Process evaluation qualitative questions and methods 
PROCESS: RESEARCH QUESTION DATA COLLECTION 
Usual care: How does organisation of care for 
patients with multi-morbidity vary across 
practices and over the timeframe of the trial? 
Descriptive data about organisation of care and 
appointment arrangements collected from informal 
interviews at time of recruitment and by contact with 
practice manager later in trial 
Initial response of practices to training: What is 
the response of practice staff to the 
intervention training? Whether and how do 
practices plan to or initially reorganise their 
care to deliver the different elements of the 
intervention?  
Participant and trainer evaluation of all training 
sessions. Non-participant observation of some training 
sessions. Semi-structured interview with lead GP and 
practice manager in up to 5 case study practices and 
some other participating practices, in the 4 weeks 
after the initial training. 
Nature and fidelity of the intervention: How is 
the appointment system reorganised (or not) to 
deliver continuity? What is the actual content of 
3D assessments, and does it match what was 
intended by the research team? What aspects 
of the intervention seem to be most (and least) 
effective, and how does this vary with patient 
circumstances and practice context? How could 
the intervention be improved? 
Non-participant observation of appointment booking 
at the reception desk and by telephone in case study 
practices. 
Audio or video recordings and/or observation of a 
sample of 3D assessment appointments in case study 
practices and some in other participating practices 
(approximate total n=20). 
Semi-structured interviews at 1 or 2 time points with 
practice manager, receptionist, practice nurses and 
GPs (approx. 8 interviews per case study practice, plus 
some in other participating practices approx. 40 total). 
Review of log of contacts with hospital physician 
supplemented by brief interview if indicated 
Maintenance: Whether and how do practices 
maintain the reach and fidelity of the 
intervention over time? What are the barriers 
to, and facilitators of successful maintenance? 
Semi-structured interview with lead GP and practice 
manager towards the end of trial. Interview with 
practice champions. (Number included in interviews 
above) 
Patient perspectives: How do patients perceive 
the changes to their care and what is their 
experience of the 3D consultations? 
Semi-structured interviews and focus groups with up 
to 6 patients per case study practice and some other 
practices participating in the trial (n= 30 total 
approx.), purposively sampled for heterogeneity in 
age, sex, socio-economic status and LTCs. Interviews 
will in some cases follow observed consultations in 
order to evaluate the consultation. 
 
10.7 Commissioners 
We recognise that implementation of findings from health services research can be problematic, but 
will seek to facilitate implementation by designing our intervention to be highly pragmatic and 
potentially commissionable. We will therefore additionally interview a sample of 6 commissioners (2 
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from each study area) both before and after the intervention is introduced. Before, we will interview 
them about ways to ensure that the intervention is introduced in a way which lends itself to 
commissioning, to identify barriers and facilitators to commissioning this type of service, how the 
new approach would fit with current commissioning models which are likely to be mainly in disease-
specific service silos, and the advantages and disadvantages of different approaches to incentives 
(e.g. QOF-type targets, Local Enhanced Services etc.). Towards the end of the study we will interview 
the commissioners again, showing them the findings from our research, in order to discuss with 
them the most important messages, potential barriers to implementation and how to mitigate them, 
current commissioning priorities and policy changes and implementation tools to help to ensure that 
(if effective) the intervention is commissioned in future. This may be supplemented by interviews 
with additional commissioners at later workshop/dissemination events. 
10.8 Data Analysis 
Data analysis for the process evaluation will initially focus on the individual datasets. Quantitative 
recruitment/ representativeness from all practices will be analysed using chi-squared tests for 
categorical variables and t-tests or non-parametric tests for continuous variables, and will inform 
judgements about the generalisability of the findings. Failure to deliver the intervention to target 
patients is an important potential cause of lack of effectiveness for any intervention, and will be 
examined by determining what proportion of the target population actually received any or all of the 
intervention components, and how this varies between practices. Differences between intervention 
and control practices in terms of process of care will be analysed using the same regression analysis 
as for main trial outcomes (described above). These data (for example about number of 
appointments, continuity of care, patient centred care) will also help to characterise ‘usual care’ in 
the control arm practices. 
For the optimisation phase, the focus of the qualitative data collection and analysis will be on 
practices’ response to the intervention, any issues they have with implementation, and fidelity of 
their intervention delivery to patients. Analysis will employ the ‘framework’ method [76] in order to 
quickly feed into improvements to the intervention and analysis that may be required for the main 
trial.  
For the qualitative data from the case study practices and other participating practices, analysis will 
take place alongside data collection to allow early analytic insights to inform ongoing data collection. 
Field notes from observation of training, appointment bookings and consultations will be coded 
alongside transcripts from recorded 3D consultations, interviews and focus groups, and used to 
characterise organisation and delivery of care in different contexts, as well as responses to, and 
implementation to the intervention. Emerging themes and theoretical ideas will be discussed and 
refined at team meetings throughout the research. The qualitative data from multiple sources, 
alongside the quantitative data, will allow us to build up a ‘thick description’[77] of each case study 
site, helping us to understand whether, how and why the intervention worked in each practice. 
Analysis of these data will enable us to elucidate the internal processes and interactions (e.g. staff-
staff, staff-patient) that impact the delivery, implementation and maintenance of the intervention. 
Across the cases, analysis of both qualitative and quantitative data will allow us to identify factors 
which are plausibly and/or consistently related to successful or unsuccessful delivery of the 
components of the intervention and changes to the experience of care by patients.[73,74] As 
analysis progresses, the fit of the data with models of patient centre care[40] will be evaluated, for 
example, giving attention to whether and how the intervention enhances the therapeutic alliance 
between patient and doctor. The final stage of analysis will be to draw together the findings from 
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the broader quantitative analysis and the in-depth case studies to create an understanding of why 
the intervention did (or did not) work, why this happened, and identify implications for longer-term 
implementation if appropriate.  
10.9 Unintended consequences 
There is a theoretical concern that focusing effort on one group patients (in this case multimorbidity) 
could lead to reduced efforts and reduced quality of care in the other patients.[14] In order to 
compare performance in terms of the QOF in patients with and without multimorbidity, we will 
collect anonymous data about the performance against QOF targets for all patients in participating 
practices with any of the index conditions (individually or in combination) that are included in our 
definition of multimorbidity, using electronic download from medical records. We will compare QOF 
performance in patients with and without multimorbidity in the year before and the year after the 
intervention, to check whether concentrating effort on patients with multimorbidity has any positive 
or negative impact on the care of other patients. 
Similarly, we will explore whether it is feasible to obtain anonymised data about deaths and hospital 
admissions for all patients in participating practices, as this would enable us to compare these 
outcomes in patients with and without multimorbidity in intervention and control practices (see 
section 5.1.3) 
11 Research Governance 
The trial will be conducted to protect the human rights and dignity of the participant as reflected in 
the 1996 version of the Helsinki Declaration. Patients will not receive any financial inducement to 
participate. In order to protect the trial participants the following provisions will be made/upheld; 
the trial has been designed to minimise pain, discomfort and fear and any foreseeable risk in relation 
to the treatments involved; the explicit wishes of the participant will be respected including the right 
to withdraw from the trial at any time; the interest of the patient will prevail over those of science 
and society; provision will be made for indemnity by the investigator and sponsor. 
The trial will be registered with a publicly accessible trial register (Trial registration number: 
ISRCTN06180958) 
This study will be conducted in accordance with principles of good clinical practice (GCP) and a 
favourable ethical opinion from the appropriate Research Ethics Committee and local NHS R&D 
approvals from the appropriate trusts will be obtained prior to commencement of the study. 
11.1 Ethical conduct 
We are aware that patients with multimorbidities require quite complex care. However patients will 
not be denied any form of care that is currently available in the NHS by participating in this study. 
Patients from usual care practices will still have access to NICE recommended treatments and local 
provision of services. Whereas patients from intervention practices will still have full access to their 
GP and secondary care services in addition to their 6 monthly 3D assessments.  
This study raises the following ethical issues:  
(i) Cluster level randomisation: This is a complex organisational intervention, therefore 
randomisation needs to be at the level of the organisation, ie the practice. If one tried to 
randomise by individual patients, there would be problem of contamination (GP trained in 
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the new way of working would change their ‘usual’ care practices and the study would not 
be able to test the effect of practice re-organisation). 
(ii) The role of individual consent: Cluster randomised trials have the issue that all eligible 
patients in ‘intervention’ practices will receive the intervention even though they will not 
be asked to give individual consent. This is justified because the intervention has few risks, 
and it is normal for general practices to try out new ways of working with the aim of 
improving patient care, without needing individual patient consent. However, patients will 
be asked to give consent to complete questionnaires and to allow researchers to have 
access to their notes, and only consenting patients will be included in the analysis of the 
main trial outcomes.  
(iii) Use of anonymised data: Anonymised data will be used for some analyses e.g. 
comparisons of consenting and non-consenting patients.  
(iv) Patients lacking capacity to consent: Because we wish to have broad inclusion criteria we 
will ask carers to help with completion of questionnaires where appropriate. In England, 
we will seek assent from legal guardians or consultees where potential participants do not 
have capacity to give consent themselves. In Scotland, adults lacking capacity to consent 
will be excluded from the study 
 
11.2 Safety Assessment and Adverse Events 
The study will monitor the occurrence of any serious adverse event which arises whilst the 
participant is taking part in the trial. 
11.2.1 Definitions 
An adverse event is any unexpected effect of an untoward clinical event affecting the participant. 
This is classed according to severity i.e.  
a) Non-serious adverse event (AE) – which includes discomfort or a slight worsening of 
symptoms 
b) Serious Adverse Events (SAE) – which may be particular harmful, dangerous or require 
hospitalisations.  
An SAE is defined as one of the following: 
1. results in death; 
2. is life threatening; 
3. requires hospitalisation or prolongation of existing hospitalisation; 
4. results in persistent or significant disability or incapacity; 
5. consists of a congenital anomaly or birth defect;  
6. is otherwise considered medically significant by the investigator. 
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Given that patients with multimorbidity may be heavy users of secondary care services, new medical 
diagnoses, hospital admissions and deaths are expected and will not be considered as SAEs unless it 
appears that they may have been related to the intervention of the research process. 
Hospitalisations and deaths will be counted as part of the service use data and reported as part of 
the trial analysis.  
11.2.2 Detecting and recording AEs and SAEs 
Adverse events may be reported by several methods: 
1. Directly by the participant (ie by email, phone call or voice mail message) 
2. From the participants follow up questionnaires 
3. Indirectly from family members, carers, guardians or representatives 
4. From the participants GP practice (following the patient’s 6 monthly assessment or 
information passed on from hospitals). 
 
Participants and GP practice staff will be asked to notify any adverse event which they believe may 
have occurred as a result of the trial intervention or the research process. On notification of an such 
an adverse event which may be related to the research process or intervention, a researcher should 
complete an adverse event reporting form within 5 working days, paying specific attention to 
information regarding the timescale of events i.e. when the event started, were there any specific 
changes to medication or behaviour preceding the event. Further information should be requested 
from the participant or GP/practice nurse as necessary.  
A completed form should be securely sent to the Trial Manager who will pass it onto the trial 
clinician to review. 
11.2.3 Assessment of relatedness and expectedness 
The trial clinician will make the following decisions 
1. Whether the adverse event is an AE or SAE  
2. How related is the event to the study intervention and/or research processes, according 
to the following definitions: 
Unrelated – where an event is not considered to be related to the study intervention or 
research processes 
Possibly – although a relationship to the study intervention and/or research processes 
cannot be completely ruled out, the nature of the event, the underlying disease, 
concomitant medication or temporal relationship make other explanations possible 
Probably – the temporal relationship and absence of a more likely explanation suggest the 
event could be related to the study intervention and/or research processes 
Definitely – Known effects of the study intervention and/or research processes, or based on 
challenge testing, suggest that study intervention is the most likely cause. 
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3. Expectedness of the event. Is the event an anticipated medical event even if the 
research had not been taking place? 
4. Is further action required? 
11.2.4 Reporting requirements for SAEs 
All reporting of SAEs of a related and unexpected nature will follow regulatory reporting 
requirements as set out in article 17 of the EU directive 2001. These will be reported to the sponsor 
immediately and will be reported to the REC within 7 days of the Trial Manager becoming aware of 
the event. Any relevant further information will be subsequently communicated within 8 days. In 
addition all investigators will be notified. 
The TSC will be notified immediately of all SAEs thought to be treatment or research related.  
Potential SAEs which after review are not thought to be treatment or research related will be 
brought to the TSC’s attention at their next scheduled meeting. The numbers and details of all AEs 
and SAEs will be reported to the Trial Management Group, Trial Steering Committee and Data 
Monitoring Committee. 
11.3 Monitoring 
Research procedures and progress will be constantly monitored by the Trial Management Group.  
The research team will establish processes to enable practices to regularly monitor the extent to 
which they are implementing the intervention as planned. This will include regular audits of the 
number of patients who have been invited to a 3D assessment, the proportion that have attended 
both assessments, and the continuity of care provided. In addition, each practice will have a ‘GP 
champion’ who will informally monitor progress in order to ensure that the intervention is delivered 
as intended. 
By participating in the trial, patients will receive a more intensive level of monitoring than that 
normally received in primary care. 
All aspects of the study will undergo regular external monitoring by the independent Trial Steering 
Committee (see section 9.5) and Data Monitoring Committee (section 9.6). It may also be open to 
audit and monitoring from local NHS R&Ds. 
11.4 Patient and Public Involvement 
During the development of the proposal, two patient and carer open forum meetings were held 
whereby several support groups for various LTCs, carers and patients groups from GP practices were 
invited. Patient and Public Involvement (PPI) coordinators facilitated discussions aimed at asking 
patients directly what their health issues and concerns were and what services they would like in 
order to improve management of their conditions. This helped to inform the design of the 
intervention. 
15 people were willing to continue being involved in the research and these will form a patient 
involvement group. The aim would be to meet approximately 4 times a year to advise on study 
patient information leaflets, questionnaire design, ethical issues, recruitment approaches, 
dissemination of results and impact. This group will be facilitated by CM and will be funded to attend 
PPI training workshops. Reimbursement will be provided in line with INVOLVE guidance. 
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Two members of this patient group, along with Prof James Goodwin, Head of research at Age UK will 
sit on a research advisory group and Trial Steering Committee whose role is to oversee the 
management of the research. Another member will be invited to contribute to the qualitative data 
analysis by helping to identify themes and commenting on findings. Therefore service users and 
patients will be directly involved in the research design, management, and analysis of the study.  
We will take advice and use contacts within long term conditions groups to help reporting of results 
and dissemination of the research findings on their newsletters and websites, which will greatly 
enhance the relevance and reach of the study. 
 
11.5 Confidentiality 
All eligible participants will be allocated a unique trial identification number. This number will be 
used to identify patients throughout the study. Where possible, personal identifiable data will be 
removed from all collected data and replaced with the trial id number, thereby providing a level of 
pseudo-anonymisation. Only researchers needing to make direct contact will have access to the 
password protected database which links patients’ personal details with their identifier. 
Clinical information about identifiable patients will not be released without written permission from 
the participant. The exceptions are a) if the researcher is concerned for the participant’s safety or 
well-being or b) if required for monitoring and auditing by the sponsor, regulatory authorities or by 
the REC or c) release of information to clinicians who are entitled to be aware of it as part of the 
patient’s direct clinical team e.g. their GP or GP practice staff. 
 
11.6 Data Protection 
All collection, storage, processing and disclosure of personal information will be performed in 
compliance with the Data Protection Act 1998. All investigators and study staff will uphold the Act’s 
core principles. Any communications, reports or published results will not contain any personal data 
that could allow identification of individual participants. 
All computers used to collate data will have limited access measures via user names and passwords. 
Electronic mobile devices used to collect data will be encrypted. Databases and servers are stored in 
right-restricted areas with limited access. All data will be stored in locked facilities within secure 
offices. 
 
12 Trial Management 
12.1 Funding 
Research funding has been secured from NIHR Health Services and Delivery Research Programme. 
12.2 Sponsorship 
The University of Bristol will act as sponsor for the trial.  The sponsors contact is Dr Birgit Whitman, 
University of Bristol, Research and Enterprise Development, Senate House, Bristol, BS8 1TH. 
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12.3 Insurance and Indemnity 
Normal NHS indemnity procedures will apply. The University of Bristol will also provide relevant 
public liability cover, as detailed in the certificate of insurance.  
12.4 Trial Management Group (TMG) 
The Trial Management Group will meet regularly (every 6 -8 weeks) in order to ensure that the three 
study centres are working consistently, meeting study targets and adhering to the study protocol. 
The group will consist of the CI, Trial Manager, PI and researchers from each of the recruiting centres 
with input from other members of the research team where necessary. Regular progress regarding 
study recruitment, retention, issues or complaints and adverse events will be reported and 
discussed.  
12.5 Independent Trial Steering Committee (TSC) 
An independent Trial Steering Committee will be convened comprising of an external academic chair 
(who is also an academic GP), at least two other independent members (including an independent 
statistician or trial methodologist and an independent clinician with relevant experience or 
interests), two patient representatives, the CI, PIs and other key members of the study research 
team. The TSC will meet at least annually (face-to-face or by teleconference) or more frequently at 
the request of the chair. The TSC will provide external supervision to the study and monitor the 
overall trial progress, adherence to the protocol and the implications of any new information (e.g. 
research articles or policy changes).  
12.6 Data Monitoring Committee (DMC) 
This committee will comprise of an independent chair and at least two other independent members 
including an independent statistician and a clinician with relevant interests. The CI, Trial Manager 
and Trial statistician will report to the DMC. The remit of the DMC is to monitor the trial data, in 
particular to quality control and quality assurance of data collected; the progress of the trial, 
including recruitment and retention rates and adherence to the trial protocol. A key role is to ensure 
that the dignity, rights, safety and well-being of the study participants are maintained at all stages of 
the trial. All adverse events will be reported to the committee which can have direct access to 
source data and documentation. Where possible the DMC will convene prior to the TSC and will 
report their recommendations to the TSC. 
 
12.7 Advisory Group 
An advisory group will be convened to ensure the research takes account of developments in the 
NHS. Prof James Goodwin (Head of Research, Age UK), Ms Jane Whittome (Head of Programme for 
Long Term Conditions for NHS Improving Quality), and Dr Kevin Gruffydd –Jones (RCGP) have agreed 
to join this advisory group, which will also include the chair and lay members of the TSC and will 
meet on the same day as the TSC to minimise costs and make best use of people’s time. 
 
12.8 Investigator responsibilities 
Prof Chris Salisbury is the Chief Investigator with overall responsibility for the conduct of the trial as 
well as specific responsibility for the local running of the lead recruiting site. In addition, principal 
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investigators will be responsible for the local running of the study at the remaining two recruiting 
centres (Pete Bower and Steward Mercer).  
Sara Brookes (Senior Lecturer in Medical Statistics) will supervise the statistical analysis and provide 
trials methodology expertise. Sandra Hollinghurst (Senior Lecturer in Health Economics) will lead on 
economic methods. Cindy Mann (Senior Research Nurse) will conduct the process evaluation under 
supervision of Ali Heawood (Senior Research Fellow) and Bruce Guthrie, and will co-ordinate the PPI 
and advisory groups.  
Stewart Mercer (Professor of Primary Care, Univ. of Glasgow) is an academic GP who will act as PI for 
Glasgow practices. Bruce Guthrie (Professor of Primary Care, Univ. of Dundee) is an academic GP 
with an interest in multimorbidity, guidelines and polypharmacy. He will co-lead the process 
evaluation with Ali Heawood. 
Pete Bower is Professor and Head of the Centre for Primary Care at University of Manchester. He has 
expertise in trials and mixed methods research and a focus on mental health, multimorbidity, and 
service delivery. He will be PI for Manchester practices. 
Other co-applicants Imran Rafi (Chair of Clinical Innovation & Research Centre, sits on RCGP council) 
and Adriana Gjini (NHS England, Public Health Consultant) will advise on the direction and progress 
of the study. 
Investigator responsibilities (such as obtaining informed consent, investigator documentation and 
data collection) may be delegated to an appropriate member of study site staff such as Trial 
Manager or Trial Coordinators. Coordination between the sites is the responsibility of the Chief 
Investigator and Trial Manager. 
 
13 Dissemination and projected outputs 
This project will demonstrate whether or not the new approach to managing multimorbidity in 
general practice is effective and cost-effective. Our hypothesis is that the new approach will improve 
patient outcomes in terms of health related quality of life, reduced illness and treatment burden and 
improved patient experience of well-coordinated person centred care. We anticipate that the 
intervention will be broadly cost neutral or even reduce costs for the NHS as a whole. There will be 
an increased cost from longer consultations in general practice and the financial incentive to 
practices to provide these, but this may be offset by fewer recall appointments for different 
individual conditions, fewer prescriptions and possibly fewer hospital appointments or admissions. 
The project will seek to maximise the impact of the research by adopting a model of knowledge 
transfer based on the WHO knowledge transfer framework for ageing and health. This identifies 6 
critical factors which are known to influence research impact. These factors will be addressed by 
constructing an advisory group consisting of academic leads from the study and potential users, to 
create an early and continuous dialogue between investigators and beneficiaries. Age UK have 
agreed to support this group. The academic members of this group will have expertise in the 
presentation of evidence to a wide range of audiences at national and international conferences 
focused on multi-morbidity; they will be complemented by users from the health and social care 
sectors, interested charities and the policy sector who have experience in the care of those with 
multi-morbidity, plus older people themselves, in accordance with the guidelines of the NIHR Age 
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and Ageing Group. The group will identify and develop opportunities for the dissemination and 
exploitation of research findings and insights from the study, to a wide variety of audiences as 
described above.  
As part of this research project we will produce guides for commissioners and for practices to enable 
them to implement the new approach speedily and widely throughout the country, if it is effective. 
Our collaboration with the RCGP Clinical Innovation and Research Centre will facilitate wide 
dissemination to practices, and the backing of the RCGP will help to generate momentum to 
encourage practices to take up this new approach. 
We will therefore seek to disseminate the findings from this research to the following audiences: 
13.1 Dissemination to Patients 
We will produce a short newsletter of the study results which can be distributed to all trial 
participants. The study results will be made available on the study website. With the help of the 
University of Bristol press office, we will design press releases and distribute then to local and 
national newspapers, websites and patient organisations for long term conditions (e.g. Diabetes UK, 
British Heart Foundation). We will take advice from our patient representatives an engage their 
support in disseminating findings. This includes the use of social media such as Twitter which can 
point people to the results on the study website. 
13.2 Dissemination to Health Care Professionals 
One of the co-applicants (IR) is a member of the Royal College of General Practitioners (RCGP) 
Clinical Innovation and Research Centre (CIRC). In addition to helping to identify practices to 
participate and advising on the development of the intervention, CIRC will also help to publicise the 
study findings to the RCGP’s 42,000 members. This can be achieved through its communications 
network, hosting a page about the study on the RCGP website and the production of paper and 
online good practice aids and tools. In addition, a national workshop on Multimorbidity will be 
hosted by CIRC to highlight the research and disseminate the study findings. 
13.3 Dissemination to Commissioners and Policy Makers 
Commissioners and policy makers will be invited to the CIRC national workshop as described above. 
They will be made aware of articles in the lay, professional and academic press. Policy and key 
decision makers will be targeted using co-applicants individual networks. A guide for commissioners 
will be produced and published with the help of the RCGP. The full NIHR project report will include 
an executive summary and a set summary powerpoint slides aimed at NHS managers. 
13.4 Dissemination to academics 
The results of this study will be submitted to peer reviewed, high impact medical journals and 
presented at academic conferences. We envisage, as a minimum, research papers on the study 
protocol, the randomised trial outcomes, an economic analysis of cost effectiveness, patient 
experience of the new intervention and usual care, and the process evaluation. It is the intention of 
the trial team to publish the main study results within a year of study completion. The final project 
report will be made available on the NIHR website and published in the NIHR journal series. 
14 Study conduct and end of study responsibilities 
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14.1 Protocol Amendment 
Any changes in research activity procedures, except those necessary to remove an apparent, 
immediate hazard to the participant, will be reviewed and approved by the Chief Investigator. 
Amendments to the protocol will be submitted to the REC and NHS R&Ds for approval. The sponsor 
will also be notified at this point.  
Protocol amendments may be substantial (requiring full review and favourable ethical opinion from 
the REC) or minor (not requiring review). Only once the amendment has been approved by REC and 
trust R&Ds (or acknowledged in the case of a minor amendment) can the amended protocol be 
implemented.  
14.2 Protocol Violations and Deviations 
Researchers or investigators should not implement any deviation from the protocol without 
agreement from the Chief Investigator and with REC and R&D approval, except where necessary to 
eliminate an immediate hazard to trial participants. 
In the event that a researcher inadvertently or needs to deviate from the protocol, the nature and 
reasons for the deviation will be recorded in a CRF or filenote to be kept in the study site file and a 
copy sent to the trial manager for the Trial Master File. If this necessitates a subsequent protocol 
amendment, this will be submitted to the REC and trust R&Ds for review and approval if appropriate. 
14.3 End of study Archiving  
All study documentation will be kept for a minimum of 5 years after the end of the final analysis of 
the study. All paper records will be stored in secure university storage facilities. Personal identifiable 
paper records (hard copy consent forms) will be kept separate from anonymised paper records 
(questionnaires) and will be stored in locked filing cabinets in locked offices. All electronic records 
will be stored on password protected servers on secure computer networks in the University of 
Bristol. 
14.4 End study 
Investigators and/or the TSC have the right at any time to terminate the study for clinical or 
administrative reasons. 
The investigators, with the advice of the DMC will establish a set of criteria for stopping the study 
prematurely.  
The end of the study will be reported to the REC within 90 days, or 15 days if the study is stopped 
early. The investigators will inform participants and ensure that the appropriate follow-up is 
arranged for all involved. 
A draft final report and a final summary report is required by the funder within 14 days after the 
completion date of the programme or date of termination. 
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16 Appendix A – Trial Contacts 
(Alphabetical by surname) 
Professor Pete Bower 
Professor of Health Services Research 
Centre for Primary Care 
Institute of Population Health 
University of Manchester 
Williamson Building 
Oxford Road 
Manchester M13 9PL 
Tel: (0)161 275 7638 
Email: peter.bower@manchester.ac.uk 
Dr. Sara Brookes 
Senior Lecturer in Medical Statistics,  
School of Social and Community Medicine, 
Canynge Hall 
39 Whatley Road 
Bristol BS8 2PS 
 
Tel: (0117) 928 7218  
Email: Sara.T.Brookes@bristol.ac.uk 
Dr. Ardiana Gjini 
Consultant in Public Health:  
NHS England Bath, Gloucestershire, Swindon & 
Wiltshire Area Team 
 
Tel: 
Email: a.gjini@nhs.net 
Professor Bruce Guthrie 
Professor of Primary Care Medicine 
Quality, Safety & Informatics Research Group, 
Mackenzie Building, 
Kirsty Semple Way, 
Dundee DD2 4BF 
Tel: 
Email: b.guthrie@dundee.ac.uk 
Dr. Ali Heawood 
Senior Research Fellow in Primary Care 
School of Social and Community Medicine, 
Canynge Hall 
39 Whatley Road 
Bristol BS8 2PS 
Tel: (0117) 331 3934 
Email: Ali.Heawood@bristol.ac.uk 
Dr. Sandra Hollinghurst 
Senior Lecturer in Health Economics 
School of Social and Community Medicine, 
Canynge Hall 
39 Whatley Road 
Bristol BS8 2PS 
Tel: (0117) 331 3901 
Email: S.P.Hollinghurst@bristol.ac.uk 
Cindy Mann 
Research Associate 
School of Social and Community Medicine, 
Professor Stewart Mercer 
Chair in Primary Care Research (General 
Practice and Primary Care) 
Institute of Health and Wellbeing 
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Canynge Hall 
39 Whatley Road 
Bristol BS8 2PS 
Tel: (0117) 928 7372 
Email: Cindy.Mann@bristol.ac.uk 
 
College of Medical, Veterinary and Life Sciences 
University of Glasgow 
1 Horslethill Road 
Glasgow G12 9LX 
Tel: 01413308330 
Email: Stewart.Mercer@glasgow.ac.uk 
Dr. Imran Rafi 
Chair of RCGP Clinical Innovation and Research 
Royal College of General Practitioners 
30 Euston Square 
London 
NW1 2FB 
Tel: 020 3188 7400 
Email: imran.rafi@rcgp.org.uk 
Professor Christopher Salisbury 
Professor in Primary Health Care 
School of Social and Community Medicine, 
Canynge Hall 
39 Whatley Road 
Bristol BS8 2PS 
Tel: (0117) 3314530 
Email: C.Salisbury@bristol.ac.uk 
Dr. Joanna Thorn, Health Economist 
Research Associate in Health Economics 
School of Social and Community Medicine, 
Canynge Hall 
39 Whatley Road 
Bristol 
BS8 2PS 
Tel: (0117)3314526 
Email: Joanna.Thorn@bristol.ac.uk 
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17 Appendix C – Study Flow Diagram & Conceptual Framework 
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18 Appendix D – Participant flowchart 
  
GP Practices approached + assessed for 
eligibility (Bristol, Manchester, Glasgow) 
GP Practices recruited 
Practices declined 
or excluded 
Patients identified + invited 
Patients declined 
or excluded 
Patients consent & 
Baseline data collection 
Cluster randomisation 
Intervention group Usual Care group 
6 months  
follow up 
6 months  
follow up 
12 months  
follow up 
12 months  
follow up 
Practice notes reviews 
Withdrawn/ 
No response 
Withdrawn/ 
No response 
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Summary of changes to protocol and trial 
registry 
 
Amendments to the study protocol, all approved by ethics committee. 
REC 
Amendment/ 
Protocol 
Number 
Trial Design Description of change 
Amendment 10, 
Protocol v6.0 
Follow-up 
timepoints 
Originally 6 and 12 months post recruitment in pilot 
practices, but changed to 9 and 15 months in main study. This 
was to allow for the fact that it took approximately 3 months 
after practice randomisation before the practice began to offer 
the intervention to patients due to delays in arranging staff 
training. This change was made after the main study began 
but before the final protocol was published and before any 
patients reached their first follow-up time-point. 
Amendments 2, 7, 
11, Protocol 6.1 
Process Evaluation (Not relevant to this paper) Increase number and clarify 
optional observation/audio or video recording of review 
consultations with patients and health care professionals in 
intervention and usual care practices to enhance assessment 
of variation in reviews. 
Amendment 12, 
Protocol v7.1 
Pharmacy review 
substudy 
(Not relevant to this paper). Inclusion of additional qualitative 
substudy exploring GPs and pharmacists’ views of the 3D 
pharmacy reviews 
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Changes to trial registry: ISRCTN06180958 
Date Stage of trial Changes 
28/04/2015 Following pilot 
study 
 Adults lacking capacity to consent in Scotland were 
added as an exclusion criterion, due to ethical 
committee advice. 
 Inclusion criterion were modified following the pilot 
study to remove osteoporosis and to combine chronic 
kidney disease within the cardiovascular disease group 
 Change in measure of treatment burden from Tran to 
MTBQ 
 Omission of two questions from LTC6 questionnaire 
about care being joined up and patient discussing their 
most important problems  (administrative error in 
updating registry; reinstated later) 
19/01/2016 During trial 
recruitment, 
before any 
follow-up or 
analysis 
 Follow-up time points changed from 6 and 12 months 
to 9 and 15 months, in light of experience of lag time 
before practices started delivering intervention. 
 EQ5D at 9 months specified as a secondary outcome 
(EQ5D at 15 months is primary outcome) 
02/02/2017 On completing 
statistical analysis 
plan, before any 
analysis. 
 More detailed specification of measures used for each 
outcome, due to updated requirements of registry. 
 Two questions about care coordination and care 
relating to patient’s priorities from LTC6 reinstated as 
outcomes (omitted from registry during changes of 
28/04/15 by mistake) 
 Continuity of care (an important aim of the 
intervention and specified in the SAP but not 
previously specified in registry due to oversight) 
 Number of high risk prescribing indicators added 
(always intended and specified in protocol but reliable 
measures only became possible during the trial) 
 Cost-effectiveness. Already included in the protocol, 
and aims of the study in the trial registry, but now 
specified as an outcome rather than as an approach to 
analysis (because of recent experience of publishing 
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another trial, where a journal required that cost-
effectiveness be listed as an outcome in the registry). 
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1. INTRODUCTION & PURPOSE 
This document details the rules proposed and the presentation that will be followed, as closely as 
possible, when analysing and reporting the main results from the 3D study:  A pragmatic cluster 
randomised controlled trial of a management intervention for patients with multi-morbidity in 
general practice.  
The purpose of the plan is to:  
1. Ensure that the analysis is appropriate for the aims of the trial, reflects good 
statistical practice, and that interpretation of a priori and post hoc analyses 
respectively is appropriate. 
2. Explain in detail how the data will be handled and analysed to enable others to 
perform the actual analysis in the event of sickness or other absence. 
3. Protect the project by helping it keep to timelines and within scope. 
 
Additional exploratory or auxiliary analyses of data not specified in the protocol are 
permitted, but fall outside the scope of this analysis plan (although such analyses would be 
expected to follow Good Statistical Practice). 
The analysis strategy will be made available if required by journal editors or referees when 
the main papers are submitted for publication.  Additional analyses suggested by reviewers 
or editors will, if considered appropriate, be performed in accordance with the Analysis 
Plan, but if reported the source of such a post-hoc analysis will be declared. 
 
Editorial changes 
Amendments to the statistical analysis plan will be described and justified in the final report 
of the trial and in Section 9 of this document. 
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2. STUDY DESIGN AND OBJECTIVES 
The information in these sections has been extracted from the protocol (version 7) and the 
published trial protocol1 and is presented here to place the analysis plan within the context of the 
trial aims and methods. More detail is provided in the protocol version 7 and the published 
protocol1. 
2.1. Trial aims and objectives 
2.1.1. Primary aim 
To optimise, implement and evaluate an intervention to improve the management of patients with 
multi-morbidity in general practice.  
2.1.2. Objectives 
1. To optimise the intervention through piloting in three practices  
2. To assess, through a cluster randomised controlled trial (CRCT), the impact of the 
intervention on health-related quality of life, illness burden, treatment burden, and patient 
experience as well as carer’s burden and quality of life. 
3. To assess the cost effectiveness of the intervention with an economic evaluation. 
4. To explore, through a mixed methods process evaluation, how and to what extent the 
intervention was implemented, and how/why the intervention was/not beneficial. To 
explore the advantages /disadvantages of different models of care for patients with 
comorbidity and to characterise usual care and explore any changes to management 
practices over the duration of this study in usual GP practice. 
 
This analysis plan relates to objectives 2 and 3 only. Methods and analyses relating to objective 4 are 
detailed in the process evaluation protocol paper2. 
2.2. Trial design and configuration 
This is a multi-centre, pragmatic, two-arm, practice-level CRTC comparing a new approach to the 
management of multi-morbidity in general practice versus usual care, with a parallel economic 
analysis of cost effectiveness and a mixed methods process evaluation.  
2.3. Trial centres 
Recruiting centres are based in Bristol, Manchester and Glasgow. GP practices will be recruited from 
in and around Bristol, Manchester and Ayrshire and Arran.  
2.4. Eligibility criteria 
2.4.1. Inclusion criteria for practices  
General practices with the following criteria will be approached: 
 Minimum of three GP partners  
 Minimum practice list size of 4,500 patients  
 Uses EMIS GP computer system  
2.4.2. Exclusion criteria for practices  
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There are no exclusion criteria at cluster level. 
2.4.3. Inclusion criteria for patients  
 Aged 18 or over (on date of invitation to participate) 
 Three or more Long Term Conditions (LTC) from the following list: cardiovascular disease 
(CVD) or chronic kidney disease (CKD) (including coronary heart disease, hypertension, heart 
failure, peripheral arterial disease); stroke; diabetes; COPD or asthma; epilepsy; atrial 
fibrillation; severe mental health problems; depression; dementia; learning disability and 
rheumatoid arthritis. 
2.4.4. Exclusion criteria for patients 
 Life expectancy less than 12 months  
 Serious suicidal risk  
 Known to be leaving practice within 12 months 
 Cannot complete a questionnaire in English (alone or with help) 
 If actively taking part in other research involving extra visits to GP or other health services  
 Adults lacking capacity to consent (Scotland only)  
2.5. Description of interventions 
The 3D intervention is a new approach to the management of patients with multi-morbidity. It is a 
complex intervention with four main components:  
 
 Identification and prioritisation of patients with multi-morbidity – identified patients will 
be given a ‘3D’ card and their GP records ‘flagged’. 
 Improving patient-centred care – each ‘3D’ patient will be allocated a named usual GP and 
usual practice nurse who will have responsibility for co-ordinating their care. They will be 
offered longer appointments with their usual doctor or nurse when possible. 
 Reducing the burden of illness and treatment – ‘3D’ patients will be offered a 
comprehensive assessment every 6 months instead of separate reviews for each of their 
LTCs. Each 3D assessment consists of 2 appointments approximately 1 week apart. At the 
first appointment, the patients’ usual nurse will complete a bespoke computerised template 
to address all of the 3D elements (Dimensions of health, Depression and Drugs), collect 
relevant data in relation to the patient’s combination of LTCs, and organise necessary tests. 
At the second appointment, the usual GP will review all the information, conduct a thorough 
review of medication and agree a written care plan with the patient for them to take away. 
Before the GP completes the 3D assessment a pharmacist will review each 3D patient’s 
medication list and provide recommendations for the GP. This pharmacist review will be 
undertaken once during the year for each patient. 
 Improving integration – each practice has a designated general physician who is readily 
available to discuss multi-morbidity patients with complex needs and help co-ordinate 
hospital investigations. 
To ensure the intervention is effectively implemented, it will be incentivised as if it were an 
Enhanced Service or included in the Quality and Outcomes Framework (QOF), with payment against 
targets for completion of two 3D assessments per annum. 
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Practices allocated to the control arm will continue care as usual. In most practices this will mean 
patients are recalled to different clinics to see different practice nurses to review each of their long-
term conditions. 
2.6. Randomisation procedures 
To minimise post-randomisation selection bias, practices will not be randomised until after patients 
have been identified and after the initial patient invitations have been mailed. 
Practices will be randomised using an algorithm written in advance by the Bristol Randomised Trials 
Collaboration (BRTC, UKCRC registration ID: 2) on a 1:1 ratio to receive either the intervention or 
continue care as usual (control group). Randomisation will be stratified by recruiting centre (Bristol, 
Manchester, and Glasgow) and minimised by practice deprivation level and practice size. Practices 
within each area will be randomized using a block size of two (one randomized to the 3D 
intervention and the other to usual care), to ensure balance across the treatment arms given the 
relatively small number of practices. Within each centre, each block of two practices will be 
randomized at the same time in the following way. 
Within each centre, the initial block of two will be randomized using simple randomization, such that 
one is allocated to intervention and the other control. For each subsequent block of practices, an 
algorithm (written within Stata specifically for this study) will determine the allocation of the two 
practices which creates the best balance in terms of size and deprivation and then weights the 
randomisation in favour of this allocation (rather than being deterministic); the weights being 
determined by the degree of imbalance in terms of size and deprivation (see Table 1 and example 
below).   
Example use of Table 1: Suppose the first practice in the next block of two is allocated to control and 
the second to 3D (denoted allocation 01 in Table 1) and that this would lead to an absolute 
difference in median practice size between the two treatment groups of 327, whereas if the first 
practice is allocated to 3D and the second to control (allocation 10), the absolute difference in 
median practice size is 116. Then the difference in imbalance (allocation 01 minus allocation 10) in 
terms of practice size is +211, a greater imbalance when the allocation is 01. Suppose also that 
allocation 01 would lead to an absolute difference in median deprivation score between the two 
treatment groups of 3 whereas allocation 10 would lead to an imbalance of 9. Then the difference in 
potential imbalance (allocation 01 minus allocation 10) would be -6, a greater imbalance when the 
allocation is 10. From Table 1, considering potential imbalance in both size and deprivation, this 
would result in a weighting of 0.65 in favour of allocation 01. 
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Table 1: Randomisation weightings (in favour of allocation 01a) for each block of two practices 
Practice size 
Difference in imbalance 
(allocation 01 minus 
allocation 10)a 
Deprivation score 
Difference in imbalance (allocation 01 minus allocation 10)a 
≤-12 -11 to -8 -7 to -4 -3 to 3 4 to 7 8 to 11 ≥12 
≤-900 0.80 0.80 0.80 0.8 0.75 0.65 0.50 
-899 to -600 0.80 0.80 0.80 0.75 0.65 0.50 0.35 
-599 to -300 0.80 0.80 0.75 0.65 0.50 0.35 0.25 
-299 to 299 0.80 0.75 0.65 0.50 0.35 0.25 0.20 
300 to 599 0.75 0.65 0.50 0.35 0.25 0.20 0.20 
600 to 899 0.65 0.50 0.35 0.25 0.20 0.20 0.20 
≥900 0.50 0.35 0.25 0.20 0.20 0.20 0.20 
aAllocation 01 - first practice in the block of two is allocated to control and second practice 
allocated to 3D; allocation 10 – first practice allocated to 3D and second practice to control 
 Randomisation of two practices weighted in favour of allocation 01 
 
 Randomisation of two practices weighted against allocation 01 (hence, in favour of 
allocation 10) 
2.6.1 Allocation concealment 
Practices within each of the three areas will be randomized using a block size of two. The trial 
manager (not involved in practice recruitment) will provide the senior statistician with the two 
practice IDs, size and deprivation scores. This information will then be given to the statistician only 
after practice level consent and after eligible patients have been identified and invited to take part. 
Allocations will be generated via a pre-written Stata do file. Whilst the study team are aware of the 
consistent block size of two, randomizing the two practices together will enable those recruiting 
practices to remain unaware of the next allocation. The statistician will inform the trial manager of 
the allocation of the two practices via email; the individual recruiting practices will then inform the 
practices. 
2.7. Sample size and justification 
The study is designed to detect an effect size of 0.274 standard deviations in the primary outcome of 
the EQ5D-5L. Data about the variability of the new 5 level (5L) version of the EQ5D is currently more 
limited than for the well-established 3 level (3L) version. The standard deviation of the EQ5D-3L in 
the UK general population is 0.23, rising to 0.27 in the oldest respondents (aged over 75)3. Hence an 
effect size of 0.274 would equate to a detectable difference of (0.274*0.27) = 0.074 on the EQ5D-3L, 
previously deemed to be the minimum important difference (MID)4. Although less data is available 
about the variability in the 5L version of the EQ5D than the 3L version, it seems wise to use this 
latest version of the EQ5D as it is likely to have greater sensitivity to change. 
Based on data available from our previous studies, we estimate that 2.3% of adult patients will have 
multi-morbidity in terms of three or more LTCs as defined in this study. This equates to about 108 
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patients in an average sized practice of 6000 patients i.e. 3456 potentially eligible patients in 32 
practices. Assuming 40% of patients agree to participate (n=1382), 80% are followed up to 12 
months, and an Intra-Cluster Coefficient (ICC) of 0.03 for clustering at the practice level (based on 
the WISE trial)5 this sample provides around 90% power at a 5% significance level to detect an effect 
size of 0.274 standard deviations in the EQ5D measure between the intervention and control groups.  
Since the start of this study, we are aware of two studies that have been published determining an 
MID for the EQ-5D-5L based on UK data. Nolan et al.6 published EQ5D-5L data from 616 COPD 
outpatients (mean age 70.4 years), reporting a standard deviation of 0.24 (consistent with the EQ5D-
3L and the above sample size calculation). They used distribution- and anchor-based methods to 
determine a MID for COPD of 0.051 (95% CI 0.037 to 0.063). McClure et al.7 used a simulated-
approach based on instrument-defined health transitions and identified an MID for England of 0.063 
(SD 0.013). The sample size calculation for the 3D study was determined to detect a difference of 
0.074 (based on the EQ5D-3L - the best estimate for the EQ5D-5L at the time). Interpretation of the 
3D trial findings will also include consideration of alternative MIDs (such as Nolan and McClure) 
suggested in the literature since the start of the trial, with the acknowledgement that the study may 
be underpowered to detect an MID smaller than 0.074. 
2.8. Blinding and breaking of blind 
It is not possible to mask participants or health care professionals to the group allocation of their 
practice. It is not possible to keep all members of the study team blind, however, efforts will be 
made to blind members that can be blinded, this will include the junior trial statistician, who will 
carry out the analysis of outcomes.  
2.9. Trial committees 
The Trial Management Group (TMG) will meet regularly (every 6-8 weeks) to ensure the three study 
centres are working consistently, meeting study targets and adhering to the study protocol. The 
group will consist of the CI, Trial Manager, PI and researchers from each of the recruiting centres 
with input from other members of the research team where necessary. Regular progress reports 
regarding study recruitment, retention, issues or complaints and adverse events will be reported and 
discussed. 
 
An independent Trial Steering Committee (TSC) will be convened comprising of an external academic 
chair (who is also an academic GP), at least two other independent members (which will include an 
independent statistician and an independent clinician with relevant experience or interests), two 
patient representatives, the CI, PIs and other key members of the study research team. The TSC will 
meet at least annually (face-to-face or by teleconference) or more frequently at the request of the 
chair. The TSC will provide external supervision to the study and monitor the overall trial progress, 
adherence to the protocol and the implications of any new information (e.g. research articles or 
policy changes). 
A Data Monitoring Committee (DMC) will comprise of an independent chair and at least two other 
independent members including an independent statistician and a clinician with relevant interests. 
The CI, Trial Manager and Trial statistician will report to the DMC. The remit of the DMC is to 
monitor the trial data, in particular to quality control and quality assurance of data collected; the 
progress of the trial, including recruitment and retention rates and adherence to the trial protocol. A 
key role is to ensure that the dignity, rights, safety and well-being of the study participants are 
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maintained at all stages of the trial. All adverse events will be reported to the committee which can 
have direct access to source data and documentation. Where possible the DMC will convene prior to 
the TSC and will report their recommendations to the TSC. 
2.10. Outcome measures 
2.10.1. Primary outcome 
EQ5D-5L descriptive system (measured at 15 months): The descriptive system comprises 5 
dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each 
represented in a single question. Each dimension has 5 levels: no problems, slight problems, 
moderate problems, severe problems, and extreme problems. The respondent is asked to 
indicate his/her health state by ticking (or placing a cross) in the box against the most 
appropriate statement in each of the 5 dimensions. This decision results in a 1-digit number 
expressing the level selected for that dimension. The digits for 5 dimensions can be combined 
in a 5-digit number. These are then transformed onto a single continuous scale, using a value 
set, summarising the respondent’s health state. The scale is anchored at 1 (full health) and 0 
(a state equivalent to dead); a health state considered to be worse than death is given values 
less than 0.  
2.10.2. Secondary outcomes 
Whilst the primary time point for analyses is 15 months the 3D trial will also consider the potential 
effectiveness of the 3D intervention at 9 months. Secondary analyses will consider the primary and 
secondary outcomes at 9 months, rather than employing repeated measures analyses which would 
estimate the effectiveness of the 3D intervention over the duration of the study and examine if 
there was a differential effect across time. It is plausible that the 3D intervention will be effective in 
the short-term only with any effects disappearing by 15 months, this may still warrant its 
implementation into primary care practice and so its effectiveness at 9 months should be formally 
tested within this study. 
 
The table below lists the secondary outcomes to be considered in analyses and the time points at 
which they will be measured (T0=baseline; T1=9 months; T2=15 months). Analyses for each 
secondary outcome will include adjustment for the relevant measure at baseline (T0). 
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Table 2: Secondary outcomes to be collected in the 3D study, to be compared between trial arms  
Secondary outcome Source Scale Time point 
T0 T1 T2 
Experience of holistic patient-centred care 
CARE measure of relational empathy (GP) Questionnaire - 10 items 10-50 ✓ ✓ ✓ 
CARE measure of relational empathy (nurse) Questionnaire - 10 items 10-50 ✓ ✗ ✓ 
Care related to patients’ priorities (LTC6) Questionnaire – 1 item 1-4 ✓ ✓ ✓ 
Care which is joined up (LTC6) Questionnaire – 1 item 1-4 ✓ ✓ ✓ 
PACIC measure of chronic disease 
management 
Questionnaire - 20 items 1-5 ✓ ✓ ✓ 
Overall satisfaction  Questionnaire – 1 item 1-5  ✓ ✓ ✓ 
Burden of illness measures 
EQ5D-5L Questionnaire -5 items  ✓ ✓ ✗1 
Self-rated health Questionnaire – 1 item 1-5  ✓ ✓ ✓ 
Bayliss measure of illness burden Questionnaire – 27+ items 0-1452 ✓ ✓ ✓ 
HADS Anxiety score Questionnaire - 7 items  0-21 ✓ ✓ ✓ 
HADS Depression score Questionnaire - 7 items 0-21 ✓ ✓ ✓ 
Burden of treatment 
Multimorbidity Treatment Burden 
Questionaire3 
Questionnaire - 10 items  0-100 ✓ ✓ ✓ 
Medication adherence: MMAS-8 Questionnaire - 8 items  0-8 ✓ ✓ ✓ 
Number of drugs prescribed4 Practice records  ≥0 ✓ ✗ ✓ 
Number of high risk prescribing indicators  Practice records  ≥0 ✓ ✗ ✓ 
Process measures5 
Continuity of care - COC index Practice records  0-1 ✓ ✗ ✓ 
Continuity of care - Visit Entropy  Practice records  0–log2(1/k6)1 ✓ ✗ ✓ 
Quality of disease management7 Practice records 0-100 ✓ ✗ ✓ 
Number of hospital admissions  CSU data8 ≥0 ✓ ✗ ✓ 
Number of outpatient attendances  CSU data8 ≥0 ✓ ✗ ✓ 
1 EQ5D-5L is also measured at 15 months; this is the primary outcome for the study not a secondary outcome 
2 No ceiling score, thus no maximum, respondent can add extra items (note: in 3D questionnaire only 2 extra 
conditions can be added hence maximum is inferred).  
3 Questionnaire developed for this trial 
4 Number of different types of drugs prescribed in the previous 3 months (different prescriptions of same drug 
or different dosages/formulations of same drug will not be counted as additional prescriptions). 
5 Whilst process measures, these outcomes are included as secondary outcomes as a primary aim of the study 
was to consider these as measures of whether the 3D intervention is effective. 
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6 k is the total number of possible providers 
7 Percentage of relevant Quality and Outcomes Framework (QOF) indicators met by each patient.  
8 CSU data if available, otherwise patient questionnaire  
Table 3: Carer secondary outcomes to be collected for 3D study, to be compared between trial 
arms 
Secondary outcome Source Scale Time point 
T0 T1 T2 
Carer experience scale Questionnaire - 6 items 0-100 ✓ ✓ ✓ 
EQ5D-5L carer score1 Questionnaire - 5 items -1 to 1 ✓ ✓ ✓ 
Multimorbidity Treatment Burden 
Questionnaire1,2 
Questionnaire – 16 items3 Scale still under 
development 
✓ ✓ ✓ 
1 Not listed in the trial registry  
2 Questionnaire developed for this trial 
3 The scoring system for the Multimorbidity treatment Burden Questionnaire is still under development; it is 
possible that not all 16 items will be used in the final score.  
 
The number of carers with completed questionnaires is small, hence analyses will be exploratory in 
nature. 
2.10.3 Process measures 
Table 4 presents the process measures to be considered in analyses and the time points at which 
they will be measured. 
 
Table 4: Patient level process of care measures to be collected in the 3D study, to be compared 
between trial arms 
Process measure Source Scale Time point 
T0 T1 T2 
Number of primary care 
consultations with GP 
Practice records 
electronic extract 
≥0  ✓ ✗ ✓ 
Number of primary care 
consultations with nurse 
Practice records 
electronic extract 
≥0 ✓ ✗ ✓ 
Mean duration of face to face 
consultations in surgery with GP1 
Practice records 
electronic extract 
≥0 (mins) ✓ ✗ ✓ 
Mean duration of face to face 
consultations in surgery with 
nurse2 
Practice records 
electronic extract 
≥0 (mins) ✓ ✗ ✓ 
Number of different review 
consultations3  
Practice records 
electronic extract 
≥0 
 
✓ ✗ ✓ 
At least one review received Practice records 
electronic extract 
0 (No), 1 (Yes) ✓ ✗ ✓ 
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1 Face to face consultations only because duration of telephone consultations and home visits are not reliably 
recorded 
3 Include all the chronic disease review codes including codes for 3D nurse review and GP review (nurse and GP 
reviews counted as separate reviews). Within each patient sort by date, and delete duplicate codes on one 
date, so that if they have several different diseases coded on the same day this just counts as one review. Then 
count how many review consultations each patient had.  
The number of chronic disease reviews for diabetes (based on diabetic foot risk assessment), 
asthma, COPD, dementia, mental health and rheumatoid arthritis will be summarised for each 
treatment group. Percentages will be presented using the number of patients having that disease as 
the denominator. No hypotheses tests will be carried out comparing the groups.  
Table 5 presents additional process measures to be reported for the 3D intervention arm only. There 
will be no comparative analyses. 
Table 5: Patient level process of care measures to describe implementation of the intervention 
(descriptive data, collected in the intervention arm only) 
Process measure Source Scale Time point 
T0 T1 T2 
Number of nurse 3D reviews Practice records  0, 1, 2 ✗ ✗ ✓ 
Number of GP reviews Practice records  0, 1, 2 ✗ ✗ ✓ 
Compliance1 Practice records  None, partial, 
full reviews 
✗ ✗ ✓ 
Most important problem noted Practice records  0 (No), 1 (Yes) ✗ ✗ ✓ 
EQ5D pain question noted Practice records  0 (No), 1 (Yes) ✗ ✗ ✓ 
PHQ9 entered Practice records  0 (No), 1 (Yes) ✗ ✗ ✓ 
Medication reviewed by 
Pharmacist (at least one comment 
entered) 
Practice records  0 (No), 1 (Yes) ✗ ✗ ✓ 
Medication adherence noted Practice records  0 (No), 1 (Yes) ✗ ✗ ✓ 
First patient goal noted Practice records  0 (No), 1 (Yes) ✗ ✗ ✓ 
First plan noted (‘what patient can 
do’) 
Practice records  0 (No), 1 (Yes) ✗ ✗ ✓ 
First plan noted (‘what GP can do’)  Practice records  0 (No), 1 (Yes) ✗ ✗ ✓ 
Patient agenda printed2 Practice records  0 (No), 1 (Yes) ✗ ✗ ✓ 
3D plan printed2 Practice records  0 (No), 1 (Yes) ✗ ✗ ✓ 
Number of times hospital physician 
was contacted 
Physician records ≥0 ✗ ✗ ✓ 
1 Compliance defined as: full – two GP 3D appointments and two nurse 3D appointments; ‘partial’ – at least 
one GP or nurse 3D appointment; and ‘none’ – no GP 3D appointment and no nurse 3D appointment (see 
section 6.5.3).   
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2 not available in practices in Scotland 
 
3. GENERAL ANALYSIS CONSIDERATIONS 
3.1. Analysis populations 
Full analysis set: All patients that consent to take part in the study within a randomized practice.  
These participants (practices) will be analysed in the groups to which they were allocated, 
disregarding protocol deviations or non-compliance. Missing data will be imputed using multiple 
imputation modelling (see section 3.3). Patients who have not completed the EQ5D-5L because they 
are deceased will be recorded as having a value of 0. 
Complete cases set: All patients that consent to take part in the study within a randomized practice.  
These participants (practices) will be analysed in the groups to which they were allocated, 
disregarding protocol deviations or non-compliance. Missing data will not be imputed. Patients who 
have not completed the EQ5D-5L because they are deceased will be recorded as having a value of 0. 
3.2. Derived variables 
3.2.1 Primary outcome 
A UK value set for the EQ5D-5L is now available8, along with a Stata do-file to transform the five 
EQ5D responses into a single value summarising the respondents’ health state. 
3.2.2 Secondary outcomes 
CARE – 10 item questionnaire (each scored between 1-5), total score is summation of individual 
scores.9 
PACIC – 20 item questionnaire (each item scored 1-5), overall score is an average of all 20 items.10 
EQ5D-5L (at 9 months): As calculated for patients in primary outcome. 
Bayliss – For each of 27 chronic conditions respondents select those that they experience and rate 
each selected condition on a five-point scale from 1 (interferes with daily activities “not at all”) to 5 
(interferes with daily activities “a lot”). Respondents are additionally allowed to add medical 
conditions not already on the list. The overall score representing level of morbidity is then the sum 
of conditions selected weighted by the level of interference assigned to each (that is, the sum of the 
interference scores).11 
HADS: Anxiety score – simple addition of the relevant 7 questions; Depression score – simple 
addition of the relevant 7 questions.12  
Multimorbidity Treatment Burden Questionnaire – 10 items each scored 0-4. Total score is 
calculated by calculating the average score for each patient and then multiplying by 2.5 to get a 
value 0-100. 
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MMAS – 8 item questionnaire, 74-76 with 7 questions being binary outcome assigned values 0 or 1, 
and a single question has values 4, 3, 2, 1 or 0. i 
Number of high risk prescribing indicators – This is the number of adverse warnings triggered and 
can be from 0 upwards.14 
Continuity of care: Visit entropy will be used to measure the continuity of care.  
A patient’s visit to a healthcare provider can be considered a discrete random variable X. Then X can 
take on k distinct levels, one for each healthcare provider the patient could visit. It has a probability 
distribution function p(x) that represents the probability of visiting each healthcare provider.  
Visit Entropy H(X) of a discrete random variable X can be calculated as15: 
H(𝐗) =  − ∑ 𝑝(𝑥𝑖)𝑙𝑜𝑔2 𝑝(𝑥𝑖)
𝑘
𝑖=1
 
and the probability of visiting the ith provider is estimated as: 
?̂?(𝑥𝑖) ≈
𝑛𝑖 +
1
𝑘⁄
𝑁 + 1
 
Where ni is the number of observed visits to the ith provider, k is the total number of possible 
providers, and N is the total number of observed visits. 
H(X) approaches its minimum value of zero when a patient has perfect continuity of care, visiting 
only their primary physician, and approaches its maximum when there is no continuity of care. 
Visit entropy is a relatively new measure, and is less well recognised than other measures for 
continuity of care. For this reason, continuity of care index (COCI) will also be considered for 
comparison.  
Continuity of care index (COCI) formula16:  
𝐶𝑂𝐶𝐼 =  
(∑ 𝑛𝑗
2) − 𝑁𝑀𝑗=1
𝑁(𝑁 − 1)
 
Where N is the total number of visits; nj is the number of visits to the jth different provider, where j= 
1, 2, 3, … M, and M is the number of potential available providers.  
Carers’ experience scale – 6 item questionnaire (each item has 3 possible responses). Preference-
based index values are available to transform the 6 responses to a profile measure value between 0 
and 10017. 
EQ5D-5L (carers): As calculated for patients in primary outcome. 
Multimorbidity Treatment Burden Questionnaire (carers) – development of final scoring system 
still under-development. 
Quality of disease control – This is based on the Quality and Outcomes Framework (QOF) indicators 
and uses the ‘patient average’ method of Reeves et al18. It will be measured as a percentage for each 
                                                          
i A scoring algorithm was included in the SAP but has been redacted because a condition of MMAS8 licence is 
that the data are scored using proprietary software provided by MMAS research and the scoring algorithm is 
not disclosed. Use of the ©MMAS is protected by US Copyright laws. Permission for use is required. A licence 
agreement is available from Donald E Morisky, MMAS Research LLC 14725 NE 20th St Bellevue WA 98007 or 
from dmorisky@gmail.com. 
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individual patient, where it represents the percentage of QOF chronic disease management 
indicators that apply to that patient which were successfully met.   
 
3.3. Procedures for missing data 
Missing data may arise as some participants may not return their questionnaires. It is anticipated 
that proportions with missing data will be similar between the two randomization arms but this will 
be examined and reported. Baseline characteristics will be compared between participants with and 
without 15-month follow-up data. In all tables missing data will be indicated by footnotes. 
The primary analysis for EQ5D-5L (section 6.2) will include the full analysis set (section 3.1), including 
all patients in the groups to which they were allocated and imputing missing data. Reasons for 
missingness will be explored. Missing data will be imputed using multiple imputation techniques 
such as multiple imputation by chained equations (MICE). Imputation models will include baseline, 9 
month and 15 month EQ5D-5L data (as available), intervention arm, stratifying/minimisation 
variables, as well as other variables such as baseline covariates and auxiliary covariates that are 
informative of missingness. To allow for clustering in Stata, imputations will be performed separately 
for each practice if possible. The same imputation models will be used for the primary analysis and 
the economic evaluation if possible. The influence of missing data on the primary analysis will be 
investigated in sensitivity analyses using complete case data only (section 6.5).  
The analyses of secondary outcomes will use complete case data only. The only exception to this is 
for secondary outcomes derived from several items within a validated questionnaire, where 
questionnaire guidelines specifically state that an overall score can be derived even in the presence 
of missing data for one (or more) item(s). For example, for HADS anxiety and depression scores, 
questionnaire guidelines state that the score for a single missing item from a subscale is inferred by 
using the mean of the remaining six items; however, if more than one item is missing from that 
subscale the overall score is missing (and the observation excluded from the analysis). The numbers 
(percentage) of missing data will be presented in tables of secondary outcomes.  
3.4. Study centre effects 
Randomisation is at the general practice (centre) level; the effect of practice will be taken into 
account as a random effect in multi-level regression models.  
3.5. Outliers 
Data will be checked for validity, each variable will be examined separately, and any outliers (> 3SD 
of the mean) will be checked for entry errors. Where no error is found, the variable will be checked 
for concordance with other variables, differences will be noted. We will also examine for influential 
observations (Cooks distance19) in the main analysis models. Outliers and influential observations 
will be noted. Sensitivity analyses removing outliers will be conducted. 
3.6. Data cut-off 
The cut-off for outcome data to be included in the analyses is 30 June 2017. 
4. DESCRIPTION OF PARTICIPANT CHARACTERISTICS 
4.1. Disposition 
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A flow of clusters (general practices) and participants through the trial will be summarised in 
a CONSORT diagram that will include the eligibility, reasons for exclusion, patients 
consenting, practices randomised to the two treatment groups, losses to follow up and the 
numbers analysed (for the primary outcome). 
4.2. Baseline characteristics 
The distributions of continuous variables will be examined. If data are approximately normally 
distributed, then the variable will be summarised in terms of the mean and standard deviation. For 
continuous variables that are not normally distributed median and inter quartile range (IQR) will be 
presented to summarise the variable. Categorical data will be summarised in terms of frequency 
counts and percentages. We will summarise all variables by trial arm, at both the cluster (practice) 
level and individual-level summary data. No formal statistical comparisons will be undertaken. 
5. ASSESSMENT OF STUDY QUALITY 
5.1. Eligibility checks 
The numbers of patients who were eligible (identified as having multimorbidity), randomly 
selected, invited to participate (some excluded due to terminal illness for example), and 
agreeing to participate in the trial (and reasons for exclusion/no consent) will be reported in 
the CONSORT Flow Diagram. Amongst those eligible and invited to participate, socio-
demographic and baseline characteristics will be compared between those consenting and 
those either refusing consent/not responding. 
5.2. Study completion   
Final follow up is at 15-month post-randomisation. The numbers of patients followed-up and lost to 
follow-up will be reported for each treatment arm in the CONSORT Flow Diagram. 
5.3. Compliance/ Fidelity  
Fidelity will be considered and examined in detail within the process evaluation (qualitative aspects 
of the process evaluation will be described elsewhere). Quantitative measures are detailed in Table 
5 above and will be reported for the 3D intervention group only.  
Compliance (at the patient level) will be defined as ‘full’ – two GP 3D appointments and two nurse 
3D appointments attended; ‘partial’ – at least one GP or nurse 3D appointment attended, but not 
full attendance; and ‘none’ – no GP 3D appointment and no nurse 3D appointment attended. The 
percentage of patients in each of these categories will be reported for the 3D intervention arm.  
5.4. Protocol deviations 
Any protocol deviations will be fully documented. 
6. ANALYSIS OF EFFECTIVENESS 
The reporting and presentation of data from this trial will be in accordance with the CONSORT 
guidelines for cluster randomized trials20. STATA 14.1 will be used for all statistical analysis. 
6.1. Summary of primary and secondary outcomes 
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The primary outcome will be summarised for each treatment group as the mean (SD) or median 
(IQR) as appropriate. Continuous secondary outcomes will be summarised as mean (SD) or median 
(IQR) as appropriate. Binary/ordinal data will be summarised in terms of frequency counts and 
percentages. 
6.2. Primary analysis 
The tested null hypothesis is that the mean quality of life (measured by the EQ5D-5L) for patients 
receiving the 3D intervention is the same as for those receiving usual care at 15 months follow up. 
Primary analysis will take the form of mixed-effects multivariable linear regression, adjusted for 
practice (random effect to account for clustering), minimisation variables (practice size and practice 
deprivation score) and patient baseline EQ5D-5L. The results will be presented as the difference 
between group means, corresponding 95% confidence interval and P-value. The intra-class 
correlation (ICC) will also be reported, with a 95% confidence interval. Practices/patients will be 
analysed in the groups to which they were allocated and missing data will be imputed (section 3.3). 
The distribution of EQ5D-5L and model residuals will be examined (a suitable transformation or a 
boot-strapped 95% confidence interval accounting for clustering21 will be considered if necessary). 
6.3. Secondary analyses 
All analyses of secondary outcomes will be adjusted for the baseline measure of the outcome (if 
available) and minimisation variables. Patient level analyses will also adjust for practice (as a random 
effect). All secondary outcomes will be considered at 9 and 15 months. 
The list of variables and planned models of analysis are given in the table below. Distributional 
checks will be carried out for all outcomes and the most appropriate models selected (for example, 
for ordinal outcomes mixed-effects ordered logistic models will be performed and assumptions 
regarding the ordinal nature of responses tested; if not valid alternative multinomial models will be 
employed). The effect, 95% confidence interval and P value will be reported for each model along 
with the ICC if possible. 
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Table 6: Planned analyses - Patient level secondary outcomes  
Outcomes  Type of variable Type of model1   
CARE measure of relational empathy 
(GP) 
Continuous  Mixed-effects linear regression  
CARE measure of relational empathy 
(nurse) 
Continuous  Mixed-effects linear regression  
Care related to patients’ priorities 
(LTC6) 
Discrete (ordinal) Mixed-effects ordered logistic 
regression   
Care which is joined up (LTC6) Discrete (ordinal) Mixed-effects ordered logistic 
regression   
PACIC measure of chronic disease 
management 
Continuous Mixed-effects linear regression 
Overall satisfaction  Discrete (ordinal) Mixed-effects ordered logistic 
regression   
EQ5D-5L Continuous  Mixed-effects linear regression  
Self-rated health Discrete (ordinal) Mixed-effects ordered logistic 
regression   
Bayliss measure of illness burden Continuous  Mixed-effects linear regression  
HADS Anxiety score Continuous  Mixed-effects linear regression  
HADS Depression score Continuous  Mixed-effects linear regression  
Multimorbidity Treatment Burden 
Questionnaire 
Continuous  Mixed-effects linear regression  
Medication adherence: MMAS-8 Continuous  Mixed-effects linear regression  
Number of drugs prescribed Count data  Poisson regression random effects 
Number of high risk prescribing 
indicators  
Count data  Poisson regression random effects 
Continuity of care - COC index Continuous  Mixed-effects linear regression  
Continuity of care - Visit Entropy  Continuous  Mixed-effects linear regression  
Quality of disease management Continuous  Mixed-effects linear regression  
Number of hospital admissions  Count data  Poisson regression random effects 
Number of outpatient attendances  Count data  Poisson regression random effects 
1Analyses will be dependent on distributional checks 
 
Table 7: Planned analyses - Carer secondary outcomes 
Carer secondary outcome  Type of variable  Type of model1  
Carer experience scale Continuous Mixed-effects linear regression 
EQ5D-5L carer score Continuous  Mixed-effects linear regression 
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1Analyses will be dependent on distributional checks 
 
6.4. Process of care measures 
Table 8: Planned analyses – Patient level process of care measures 
1Analyses will be dependent on distributional checks 
 
Other process measures collected at 15 months in the intervention group only (reported in Table 5) 
will be reported with descriptive statistics. For several measures percentages will be reported both 
as the percentage of all patients recruited to the intervention arm and the percentage of patients 
receiving at least one nurse or GP review (as appropriate). See Table 9 below.   
 
Table 9: Descriptive statistics - Patient level process of care measures collected in the intervention 
arm only 
Process measure Type of 
variable 
Summary 
statistics 
Denominator used in percentage 
All patients 
in 
intervention 
arm 
All those 
having at 
least one 
nurse review 
All those 
having at 
least one GP 
review 
Number of nurse 3D reviews Ordinal N (%) ✓ NA NA 
Number of GP reviews Ordinal N (%) ✓ NA NA 
Compliance1 Ordinal N (%) ✓ NA NA 
Most important problem 
noted 
Binary N (%) ✓ ✓ NA 
Multimorbidity treatment Burden 
Questionnaire (carers) 
Continuous Mixed-effects linear regression 
Process measure  Type of variable  Type of model1  
Number of primary care consultations 
with GP 
Count data Poisson regression random effects 
Number of primary care consultations 
with nurse 
Count data  Poisson regression random effects 
Mean duration of face to face 
consultations in surgery with GP 
Continuous  Mixed-effects linear regression  
Mean duration of face to face 
consultations in surgery with nurse 
Continuous  Mixed-effects linear regression  
Number of different review consultations Count data Poisson regression random effects 
At least one review received Binary  Mixed-effects logistic regression 
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EQ5D pain question noted Binary N (%) NA ✓ NA 
PHQ9 entered Binary N (%) ✓ ✓ NA 
Medication reviewed by 
Pharmacist (at least one 
comment entered) 
Binary N (%) ✓ NA ✓ 
Medication adherence noted Binary N (%) ✓ NA ✓ 
First patient goal noted Binary N (%) ✓ NA ✓ 
First plan noted (‘what 
patient can do’) 
Binary N (%) ✓ NA ✓ 
First plan noted (‘what GP 
can do’)  
Binary N (%) ✓ NA ✓ 
Patient agenda printed1 Binary N (%) ✓2 ✓2 NA 
3D plan printed1 Binary N (%) ✓2 NA ✓2 
Number of times hospital 
physician was contacted 
Count Median 
(IQR) 
NA NA NA 
1 Data not available in practices in Scotland 
2 Denominators include only those recruited from England 
6.5. Sensitivity analysis 
The analyses presented above make a number of assumptions about the data (for example, the 
treatment groups are balanced, all patients have received the allocated treatment, all patients 
completed questionnaires at the correct time point). Sensitivity analyses will consider whether the 
conclusions drawn in the primary analysis are sensitive or robust to different assumptions made. 
6.5.1 Baseline imbalance 
Baseline characteristics will be compared between the treatment groups and the magnitude of any 
differences considered in terms of their potential clinical importance (following discussion with 
clinicians). Where important differences exist, baseline characteristics will be adjusted for in 
sensitivity analyses.  
6.5.2 Missing data 
The impact of missing data on the primary analysis will be explored by conducting complete case 
analyses (using the complete cases data set (see section 3.1). 
6.5.3 Non-compliance 
If compliance is less than 90% we will also perform a complier average causal effect (CACE) analysis 
for the primary analysis of EQ5D-5L. Compliers can only be observed amongst those randomized to 
the 3D arm. Compliance will be defined as ‘full’ – two GP 3D appointments and two nurse 3D 
appointments attended; ‘partial’ – at least one GP or nurse 3D appointment attended but not full 
compliance; and ‘none’ – no GP 3D appointment and no nurse 3D appointment attended. These 
three categories will be compared in terms of key baseline characteristics. Sensitivity analysis 
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considering the complier average causal effect (CACE), will include two analyses with a dichotomous 
indicator variable for compliance: one analysis will amalgamate patients in the ‘full’ and ‘partial’ 
groups; the other will combine those in the ‘none’ and ‘partial’ groups.  
The CACE estimates will be obtained using instrumental variable regression including the same 
variables used in the primary analysis, randomized group as an instrumental variable and the 
indicator variable for compliance. 
 
6.5.4 Time of questionnaire return 
It is likely that there will be variation in the time at which questionnaires are completed. In 
sensitivity analyses, time of completion will be included as a covariate. 
6.5.5 Outliers/influential values 
The impact of outliers/influential values will be explored by removal of such observations from the 
analyses. 
6.5.6 Treating deceased patients as missing for EQ5D-5L 
As an additional sensitivity analysis, we will investigate the impact of treating the deceased 
as having a missing score for EQ5D-5L at 15 months rather than imputing a value of zero. This 
analysis will be performed using the complete case dataset.  
6.6. Potential effect modifiers 
Potential effect modifiers, selected a priori and informed by previous evidence, will be explored 
using appropriate interaction terms added to the regression models used for the primary analysis. 
Subgroup analyses of the primary outcome will explore differences in the effectiveness of the 3D 
intervention compared to usual care according to baseline measures of: 
 
 Participant age (< median / ≥ median of consenting participants); 
 Number of long term conditions as defined in section 2.4.3 (< median / ≥ median of 
consenting participants); 
 Deprivation (quartiles of consenting participants); 
 Depression alongside physical health problems (presence/absence). 
Subgroup analyses are likely to be insufficiently powered since the trial was not powered to 
specifically test these effects. These subgroup analyses will therefore be hypothesis generating and 
will focus on interpretation of 95% confidence intervals rather than P-values.  
6.7 Withdrawal rates 
It is anticipated that a small number of patients will withdraw from each treatment group. 
Withdrawal refers to patients who actively decline further participation in the trial or are withdrawn 
by their practice (e.g. due to other illness, moving practice) and for whom there is no subsequent 
data collection. For each treatment group numbers and percentages of patients withdrawing will be 
reported along with reasons for withdrawal. Baseline characteristics will be compared between 
those who withdrew and those who did not in both treatment groups to look for differential 
withdrawal between the groups.  
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7. ANALYSIS OF SAFETY 
In this population (older persons with multiple LTCs) a high number of adverse events (AE) are 
anticipated in both treatment groups, hence attention will be given only to serious adverse events 
(SAE) which may be related to the intervention or the research process (serious adverse reactions). 
7.1. Serious adverse reactions 
All reporting of SAEs of a related and unexpected nature will follow regulatory reporting 
requirements as set out in article 17 of the European Union Directive 2001. These will be reported to 
the sponsor immediately and will be reported to the REC within 7 days of the Trial Manager 
becoming aware of the event. Any relevant further information will be subsequently communicated 
within 8 days. In addition, all investigators will be notified. The TSC will be notified immediately of all 
SAEs thought to be treatment or research related. Potential SAEs which after review are not thought 
to be treatment or research related will be brought to the TSC’s attention at their next scheduled 
meeting. The numbers and details of all SAEs will be reported to the Trial Management Group, Trial 
Steering Committee and Data Monitoring Committee. 
For each treatment group the number and percentage of patients experiencing a serious adverse 
event, which appeared to be related to the intervention or the trial, will be reported. Given that 
patients with multimorbidity may be heavy users of secondary care services, new medical diagnoses, 
hospital admissions and deaths are expected and will not be considered as potential serious adverse 
events unless anyone involved in the study (participants, general practice staff or research staff) 
notify the research team of any events that they consider may have been related to the intervention 
or the research process. All deaths will be investigated for relatedness by requesting the patient’s GP 
provide details of cause of death and relatedness to study. 
If there are sufficient numbers of related SAEs, logistic regression with robust standard errors (to 
account for clustering) will be used to estimate the odds ratio (3D compared to usual care) for the 
different categories of SAEs. Corresponding 95% confidence intervals and P values will also be 
presented. If sufficient numbers of patients have multiple SAEs then ordered logistic models will be 
employed (e.g. outcome may be categorised as 0, 1, 2, 3+ SAEs).  
7.1.1 Deaths 
Given the population participating in the 3D trial, some deaths are expected before the end of 
follow-up in each treatment group. Numbers and percentages in each arm will be reported. Poisson 
regression and Cox regression with random effects will be considered (as appropriate) to calculate a 
rate ratio or hazard ratio with the corresponding 95% confidence intervals and P values. Models will 
also consider minimisation variables, age, number of long standing conditions, and EQ5D-5L at 
baseline.  
 
8. CHANGES MADE TO STATISTICAL ANALYSIS PLAN 
All amendments made to the statistical analysis plan (following approval by the TMG/ DMC and TSC 
of final version 1.0) will be listed in the table below. Following each amendment, a new version of 
the analysis plan will be created and previous versions saved. 
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Table 10: Record of amendments to statistical and economic analysis plans 
Amendment Rationale Analysis 
plan 
version 
Date SAP 
amended 
Approved by 
(delete as 
appropriate) 
    TMG / DMC / TSC 
    TMG / DMC / TSC 
    TMG / DMC / TSC 
    TMG / DMC / TSC 
    TMG / DMC / TSC 
    TMG / DMC / TSC 
    TMG / DMC / TSC 
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Differences between the Statistical 
Analysis Plan and the final analysis 
There were three differences between the SAP and the final analysis conducted: 
1. In the SAP we specified that we would score the EQ-5D-5L using a UK value set which had 
recently been published.1  However, in August 2017 the National Institute for Health and 
Care Excellence (NICE) issued a position statement in which they stated that further work 
was needed to establish the validity of that value set.2 They advised that researchers should 
at present calculate utility values by mapping onto the EQ-5D-3L value set using the 
methods of Van Hout el al.3  We therefore used the Van Hout method for our analysis. 
2. In the original SAP we included details of scoring the Morisky Medication Adherence 
Questionnaire (MMAS-8), one of the secondary outcomes. However a condition of the 
MMAS licence was that the data were scored using proprietary software provided by MMAS 
research and that the scoring algorithm was not disclosed. Therefore we scored the MMAS 
using the software. 
3. In the protocol we had stated that all main analyses would be adjusted for stratification and 
minimisation variables (which is the correct approach)  whereas in the SAP we only stated 
adjustment for minimisation variables and did not mention stratification (which was an 
error).  All adjusted analyses were correctly adjusted for stratification (the site i.e. Bristol, 
Manchester or Glasgow) as well as minimisation variables, baseline values of the relevant 
outcome, and practice as a random effect (as already specified in the SAP). 
Please note that in the paper we have reported all of the primary and secondary outcomes specified 
in the SAP. There are some other exploratory analyses described in the SAP but not included in the 
paper in order to keep it to a reasonable length. All of these additional analyses have been 
conducted in line with the SAP and will be reported in the full report of the 3D study to be published 
in the NIHR Journals library after the main paper is published. 
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